WO2022100688A1 - Hpk1激酶调节剂、其制备方法与应用 - Google Patents
Hpk1激酶调节剂、其制备方法与应用 Download PDFInfo
- Publication number
- WO2022100688A1 WO2022100688A1 PCT/CN2021/130283 CN2021130283W WO2022100688A1 WO 2022100688 A1 WO2022100688 A1 WO 2022100688A1 CN 2021130283 W CN2021130283 W CN 2021130283W WO 2022100688 A1 WO2022100688 A1 WO 2022100688A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- hydrogen
- alkyl
- independently selected
- methyl
- cycloalkyl
- Prior art date
Links
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 108091000080 Phosphotransferase Proteins 0.000 title description 2
- 102000020233 phosphotransferase Human genes 0.000 title description 2
- 101100177670 Caenorhabditis elegans hpk-1 gene Proteins 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims abstract description 111
- 150000003839 salts Chemical class 0.000 claims abstract description 47
- 239000000651 prodrug Substances 0.000 claims abstract description 40
- 229940002612 prodrug Drugs 0.000 claims abstract description 40
- 239000012453 solvate Substances 0.000 claims abstract description 37
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 36
- 102100028199 Mitogen-activated protein kinase kinase kinase kinase 1 Human genes 0.000 claims abstract description 33
- 201000011510 cancer Diseases 0.000 claims abstract description 28
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 26
- 201000010099 disease Diseases 0.000 claims abstract description 24
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 24
- 230000000694 effects Effects 0.000 claims abstract description 18
- 230000028993 immune response Effects 0.000 claims abstract description 9
- 101001059991 Homo sapiens Mitogen-activated protein kinase kinase kinase kinase 1 Proteins 0.000 claims abstract description 6
- 239000001257 hydrogen Substances 0.000 claims description 521
- 229910052739 hydrogen Inorganic materials 0.000 claims description 521
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims description 379
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 293
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 212
- -1 2-(N,N-dimethylamino)ethyl Chemical group 0.000 claims description 195
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 153
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims description 143
- 150000002431 hydrogen Chemical class 0.000 claims description 143
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims description 133
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims description 98
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 93
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims description 91
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 90
- VGGSQFUCUMXWEO-UHFFFAOYSA-N Ethene Chemical compound C=C VGGSQFUCUMXWEO-UHFFFAOYSA-N 0.000 claims description 88
- 239000005977 Ethylene Substances 0.000 claims description 88
- 229910052717 sulfur Inorganic materials 0.000 claims description 74
- 229910052760 oxygen Inorganic materials 0.000 claims description 62
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 61
- 229910052757 nitrogen Inorganic materials 0.000 claims description 51
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 49
- 239000011737 fluorine Chemical group 0.000 claims description 45
- 229910052731 fluorine Inorganic materials 0.000 claims description 45
- 125000005842 heteroatom Chemical group 0.000 claims description 43
- IYABWNGZIDDRAK-UHFFFAOYSA-N allene Chemical group C=C=C IYABWNGZIDDRAK-UHFFFAOYSA-N 0.000 claims description 42
- 239000000460 chlorine Chemical group 0.000 claims description 37
- 229910052801 chlorine Inorganic materials 0.000 claims description 36
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical group [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 35
- 229910052736 halogen Inorganic materials 0.000 claims description 35
- 125000004433 nitrogen atom Chemical group N* 0.000 claims description 35
- 150000002367 halogens Chemical class 0.000 claims description 34
- 125000006552 (C3-C8) cycloalkyl group Chemical group 0.000 claims description 30
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 30
- 125000000954 2-hydroxyethyl group Chemical group [H]C([*])([H])C([H])([H])O[H] 0.000 claims description 29
- 238000006243 chemical reaction Methods 0.000 claims description 28
- 125000000623 heterocyclic group Chemical group 0.000 claims description 26
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 26
- 229920002554 vinyl polymer Polymers 0.000 claims description 26
- 125000006163 5-membered heteroaryl group Chemical group 0.000 claims description 25
- 125000000217 alkyl group Chemical group 0.000 claims description 25
- 125000000753 cycloalkyl group Chemical group 0.000 claims description 25
- 238000000034 method Methods 0.000 claims description 25
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 25
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical group [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 21
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Chemical group BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 21
- 229910052794 bromium Inorganic materials 0.000 claims description 21
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 21
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims description 20
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 claims description 18
- 239000003814 drug Substances 0.000 claims description 16
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 15
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 15
- YIBBMDDEXKBIAM-UHFFFAOYSA-M potassium;pentoxymethanedithioate Chemical compound [K+].CCCCCOC([S-])=S YIBBMDDEXKBIAM-UHFFFAOYSA-M 0.000 claims description 15
- 239000000126 substance Substances 0.000 claims description 12
- 210000004027 cell Anatomy 0.000 claims description 11
- 229940079593 drug Drugs 0.000 claims description 11
- 125000001424 substituent group Chemical group 0.000 claims description 11
- 125000001309 chloro group Chemical group Cl* 0.000 claims description 10
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 claims description 9
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 claims description 9
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 9
- 230000002378 acidificating effect Effects 0.000 claims description 9
- 238000010534 nucleophilic substitution reaction Methods 0.000 claims description 9
- 229910052763 palladium Inorganic materials 0.000 claims description 9
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 8
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 8
- 208000005017 glioblastoma Diseases 0.000 claims description 8
- 238000009169 immunotherapy Methods 0.000 claims description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 7
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 claims description 7
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 6
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 6
- 229910052751 metal Inorganic materials 0.000 claims description 6
- 239000002184 metal Substances 0.000 claims description 6
- NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 claims description 6
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 6
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims description 5
- 201000005202 lung cancer Diseases 0.000 claims description 5
- 208000020816 lung neoplasm Diseases 0.000 claims description 5
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 5
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 claims description 4
- 208000007860 Anus Neoplasms Diseases 0.000 claims description 4
- 108010074708 B7-H1 Antigen Proteins 0.000 claims description 4
- 206010005003 Bladder cancer Diseases 0.000 claims description 4
- 206010006187 Breast cancer Diseases 0.000 claims description 4
- 208000026310 Breast neoplasm Diseases 0.000 claims description 4
- 108010021064 CTLA-4 Antigen Proteins 0.000 claims description 4
- 229940045513 CTLA4 antagonist Drugs 0.000 claims description 4
- 206010008342 Cervix carcinoma Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 208000000461 Esophageal Neoplasms Diseases 0.000 claims description 4
- 206010051066 Gastrointestinal stromal tumour Diseases 0.000 claims description 4
- 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 4
- 102100034458 Hepatitis A virus cellular receptor 2 Human genes 0.000 claims description 4
- 101710083479 Hepatitis A virus cellular receptor 2 homolog Proteins 0.000 claims description 4
- 101001137987 Homo sapiens Lymphocyte activation gene 3 protein Proteins 0.000 claims description 4
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 4
- 102000017578 LAG3 Human genes 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 4
- 206010033128 Ovarian cancer Diseases 0.000 claims description 4
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 4
- 206010061902 Pancreatic neoplasm Diseases 0.000 claims description 4
- 208000002471 Penile Neoplasms Diseases 0.000 claims description 4
- 206010060862 Prostate cancer Diseases 0.000 claims description 4
- 208000000236 Prostatic Neoplasms Diseases 0.000 claims description 4
- 208000015634 Rectal Neoplasms Diseases 0.000 claims description 4
- 206010038389 Renal cancer Diseases 0.000 claims description 4
- 229940044665 STING agonist Drugs 0.000 claims description 4
- 206010039491 Sarcoma Diseases 0.000 claims description 4
- 208000000453 Skin Neoplasms Diseases 0.000 claims description 4
- 206010041067 Small cell lung cancer Diseases 0.000 claims description 4
- 208000005718 Stomach Neoplasms Diseases 0.000 claims description 4
- 229940126547 T-cell immunoglobulin mucin-3 Drugs 0.000 claims description 4
- 208000024770 Thyroid neoplasm Diseases 0.000 claims description 4
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims description 4
- 108090001012 Transforming Growth Factor beta Proteins 0.000 claims description 4
- 102000004887 Transforming Growth Factor beta Human genes 0.000 claims description 4
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 claims description 4
- 208000006105 Uterine Cervical Neoplasms Diseases 0.000 claims description 4
- 206010047741 Vulval cancer Diseases 0.000 claims description 4
- 208000004354 Vulvar Neoplasms Diseases 0.000 claims description 4
- 239000005557 antagonist Substances 0.000 claims description 4
- 201000011165 anus cancer Diseases 0.000 claims description 4
- 208000020790 biliary tract neoplasm Diseases 0.000 claims description 4
- 201000010881 cervical cancer Diseases 0.000 claims description 4
- 208000029742 colonic neoplasm Diseases 0.000 claims description 4
- 238000005859 coupling reaction Methods 0.000 claims description 4
- 210000002919 epithelial cell Anatomy 0.000 claims description 4
- 206010017758 gastric cancer Diseases 0.000 claims description 4
- 201000011243 gastrointestinal stromal tumor Diseases 0.000 claims description 4
- 201000010536 head and neck cancer Diseases 0.000 claims description 4
- 208000014829 head and neck neoplasm Diseases 0.000 claims description 4
- 201000002313 intestinal cancer Diseases 0.000 claims description 4
- 201000010982 kidney cancer Diseases 0.000 claims description 4
- 208000032839 leukemia Diseases 0.000 claims description 4
- 201000007270 liver cancer Diseases 0.000 claims description 4
- 208000014018 liver neoplasm Diseases 0.000 claims description 4
- 201000005249 lung adenocarcinoma Diseases 0.000 claims description 4
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 claims description 4
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 4
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 4
- 201000002528 pancreatic cancer Diseases 0.000 claims description 4
- 208000008443 pancreatic carcinoma Diseases 0.000 claims description 4
- 206010038038 rectal cancer Diseases 0.000 claims description 4
- 201000001275 rectum cancer Diseases 0.000 claims description 4
- 201000000849 skin cancer Diseases 0.000 claims description 4
- 208000000587 small cell lung carcinoma Diseases 0.000 claims description 4
- 229910000104 sodium hydride Inorganic materials 0.000 claims description 4
- 201000011549 stomach cancer Diseases 0.000 claims description 4
- 201000002510 thyroid cancer Diseases 0.000 claims description 4
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 4
- 201000005112 urinary bladder cancer Diseases 0.000 claims description 4
- 201000005102 vulva cancer Diseases 0.000 claims description 4
- CYPYTURSJDMMMP-WVCUSYJESA-N (1e,4e)-1,5-diphenylpenta-1,4-dien-3-one;palladium Chemical compound [Pd].[Pd].C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1.C=1C=CC=CC=1\C=C\C(=O)\C=C\C1=CC=CC=C1 CYPYTURSJDMMMP-WVCUSYJESA-N 0.000 claims description 3
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 claims description 3
- 208000005016 Intestinal Neoplasms Diseases 0.000 claims description 3
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 claims description 3
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 claims description 3
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 3
- 229940124614 TLR 8 agonist Drugs 0.000 claims description 3
- 239000000556 agonist Substances 0.000 claims description 3
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 claims description 3
- 229910000024 caesium carbonate Inorganic materials 0.000 claims description 3
- 239000003054 catalyst Substances 0.000 claims description 3
- GPAYUJZHTULNBE-UHFFFAOYSA-N diphenylphosphine Chemical compound C=1C=CC=CC=1PC1=CC=CC=C1 GPAYUJZHTULNBE-UHFFFAOYSA-N 0.000 claims description 3
- KTWOOEGAPBSYNW-UHFFFAOYSA-N ferrocene Chemical compound [Fe+2].C=1C=C[CH-]C=1.C=1C=C[CH-]C=1 KTWOOEGAPBSYNW-UHFFFAOYSA-N 0.000 claims description 3
- PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 claims description 3
- YJVFFLUZDVXJQI-UHFFFAOYSA-L palladium(ii) acetate Chemical group [Pd+2].CC([O-])=O.CC([O-])=O YJVFFLUZDVXJQI-UHFFFAOYSA-L 0.000 claims description 3
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 3
- NTTOTNSKUYCDAV-UHFFFAOYSA-N potassium hydride Chemical compound [KH] NTTOTNSKUYCDAV-UHFFFAOYSA-N 0.000 claims description 3
- 229910000105 potassium hydride Inorganic materials 0.000 claims description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 3
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 3
- 239000012312 sodium hydride Substances 0.000 claims description 3
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 claims description 3
- 229940044655 toll-like receptor 9 agonist Drugs 0.000 claims description 3
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical group FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 claims 19
- 125000000325 methylidene group Chemical group [H]C([H])=* 0.000 claims 5
- 206010066476 Haematological malignancy Diseases 0.000 claims 3
- 208000032271 Malignant tumor of penis Diseases 0.000 claims 3
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims 3
- 206010030155 Oesophageal carcinoma Diseases 0.000 claims 3
- 206010034299 Penile cancer Diseases 0.000 claims 3
- 201000009036 biliary tract cancer Diseases 0.000 claims 3
- 201000004101 esophageal cancer Diseases 0.000 claims 3
- 102100039498 Cytotoxic T-lymphocyte protein 4 Human genes 0.000 claims 1
- 201000003741 Gastrointestinal carcinoma Diseases 0.000 claims 1
- 102100024216 Programmed cell death 1 ligand 1 Human genes 0.000 claims 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 33
- 108010002838 hematopoietic progenitor kinase 1 Proteins 0.000 description 27
- YCKRFDGAMUMZLT-UHFFFAOYSA-N Fluorine atom Chemical compound [F] YCKRFDGAMUMZLT-UHFFFAOYSA-N 0.000 description 26
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 20
- 125000001153 fluoro group Chemical group F* 0.000 description 19
- 210000001744 T-lymphocyte Anatomy 0.000 description 15
- 125000004432 carbon atom Chemical group C* 0.000 description 15
- 239000000243 solution Substances 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 13
- RWRDLPDLKQPQOW-UHFFFAOYSA-N Pyrrolidine Chemical compound C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 description 13
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 13
- 125000001570 methylene group Chemical group [H]C([H])([*:1])[*:2] 0.000 description 12
- 239000000203 mixture Substances 0.000 description 11
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 9
- 150000002430 hydrocarbons Chemical group 0.000 description 9
- 239000001301 oxygen Substances 0.000 description 9
- 239000012071 phase Substances 0.000 description 9
- 229920006395 saturated elastomer Polymers 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- NQRYJNQNLNOLGT-UHFFFAOYSA-N Piperidine Chemical compound C1CCNCC1 NQRYJNQNLNOLGT-UHFFFAOYSA-N 0.000 description 8
- 239000007788 liquid Substances 0.000 description 8
- 230000015572 biosynthetic process Effects 0.000 description 7
- 239000002552 dosage form Substances 0.000 description 7
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- QUSNBJAOOMFDIB-UHFFFAOYSA-N Ethylamine Chemical compound CCN QUSNBJAOOMFDIB-UHFFFAOYSA-N 0.000 description 6
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
- BAVYZALUXZFZLV-UHFFFAOYSA-N Methylamine Chemical compound NC BAVYZALUXZFZLV-UHFFFAOYSA-N 0.000 description 6
- YNAVUWVOSKDBBP-UHFFFAOYSA-N Morpholine Chemical compound C1COCCN1 YNAVUWVOSKDBBP-UHFFFAOYSA-N 0.000 description 6
- GLUUGHFHXGJENI-UHFFFAOYSA-N Piperazine Chemical compound C1CNCCN1 GLUUGHFHXGJENI-UHFFFAOYSA-N 0.000 description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 6
- 125000001246 bromo group Chemical group Br* 0.000 description 6
- 239000002775 capsule Substances 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 6
- 239000002994 raw material Substances 0.000 description 6
- 239000011593 sulfur Substances 0.000 description 6
- 208000024891 symptom Diseases 0.000 description 6
- 239000003826 tablet Substances 0.000 description 6
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 125000002947 alkylene group Chemical group 0.000 description 5
- 239000006185 dispersion Substances 0.000 description 5
- 239000000543 intermediate Substances 0.000 description 5
- QARBMVPHQWIHKH-UHFFFAOYSA-N methanesulfonyl chloride Chemical compound CS(Cl)(=O)=O QARBMVPHQWIHKH-UHFFFAOYSA-N 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 5
- 238000002953 preparative HPLC Methods 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 239000000741 silica gel Substances 0.000 description 5
- 229910002027 silica gel Inorganic materials 0.000 description 5
- 238000003786 synthesis reaction Methods 0.000 description 5
- 238000004809 thin layer chromatography Methods 0.000 description 5
- 239000003643 water by type Substances 0.000 description 5
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 description 4
- ANIJFZVZXZQFDH-UHFFFAOYSA-N 2-bromo-5-nitro-1,3-thiazole Chemical compound [O-][N+](=O)C1=CN=C(Br)S1 ANIJFZVZXZQFDH-UHFFFAOYSA-N 0.000 description 4
- LQLJZSJKRYTKTP-UHFFFAOYSA-N 2-dimethylaminoethyl chloride hydrochloride Chemical compound Cl.CN(C)CCCl LQLJZSJKRYTKTP-UHFFFAOYSA-N 0.000 description 4
- XORHNJQEWQGXCN-UHFFFAOYSA-N 4-nitro-1h-pyrazole Chemical compound [O-][N+](=O)C=1C=NNC=1 XORHNJQEWQGXCN-UHFFFAOYSA-N 0.000 description 4
- IRAOSCSPAYZRJE-UHFFFAOYSA-N 5-bromoquinoxalin-6-amine Chemical compound N1=CC=NC2=C(Br)C(N)=CC=C21 IRAOSCSPAYZRJE-UHFFFAOYSA-N 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 4
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 108091008874 T cell receptors Proteins 0.000 description 4
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 4
- 125000003545 alkoxy group Chemical group 0.000 description 4
- 239000000427 antigen Substances 0.000 description 4
- 102000036639 antigens Human genes 0.000 description 4
- 108091007433 antigens Proteins 0.000 description 4
- HONIICLYMWZJFZ-UHFFFAOYSA-N azetidine Chemical compound C1CNC1 HONIICLYMWZJFZ-UHFFFAOYSA-N 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 210000004443 dendritic cell Anatomy 0.000 description 4
- 125000001072 heteroaryl group Chemical group 0.000 description 4
- 125000000654 isopropylidene group Chemical group C(C)(C)=* 0.000 description 4
- 239000002502 liposome Substances 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 231100000252 nontoxic Toxicity 0.000 description 4
- 230000003000 nontoxic effect Effects 0.000 description 4
- DRINJBFRTLBHNF-UHFFFAOYSA-N propane-2-sulfonyl chloride Chemical compound CC(C)S(Cl)(=O)=O DRINJBFRTLBHNF-UHFFFAOYSA-N 0.000 description 4
- 230000000069 prophylactic effect Effects 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 230000002829 reductive effect Effects 0.000 description 4
- 229930195734 saturated hydrocarbon Natural products 0.000 description 4
- 239000000377 silicon dioxide Substances 0.000 description 4
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 description 4
- OGYGFUAIIOPWQD-UHFFFAOYSA-N 1,3-thiazolidine Chemical compound C1CSCN1 OGYGFUAIIOPWQD-UHFFFAOYSA-N 0.000 description 3
- SIKXIUWKPGWBBF-UHFFFAOYSA-N 5-bromo-2,4-dichloropyrimidine Chemical compound ClC1=NC=C(Br)C(Cl)=N1 SIKXIUWKPGWBBF-UHFFFAOYSA-N 0.000 description 3
- BFRVNJRCCVCPPR-UHFFFAOYSA-N 5-chloro-6-nitroquinoxaline Chemical compound N1=CC=NC2=C(Cl)C([N+](=O)[O-])=CC=C21 BFRVNJRCCVCPPR-UHFFFAOYSA-N 0.000 description 3
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 3
- 102000008096 B7-H1 Antigen Human genes 0.000 description 3
- 102000008203 CTLA-4 Antigen Human genes 0.000 description 3
- 239000004215 Carbon black (E152) Substances 0.000 description 3
- ROSDSFDQCJNGOL-UHFFFAOYSA-N Dimethylamine Chemical compound CNC ROSDSFDQCJNGOL-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- 108010010803 Gelatin Proteins 0.000 description 3
- WTDHULULXKLSOZ-UHFFFAOYSA-N Hydroxylamine hydrochloride Chemical compound Cl.ON WTDHULULXKLSOZ-UHFFFAOYSA-N 0.000 description 3
- WRYCSMQKUKOKBP-UHFFFAOYSA-N Imidazolidine Chemical compound C1CNCN1 WRYCSMQKUKOKBP-UHFFFAOYSA-N 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 125000003342 alkenyl group Chemical group 0.000 description 3
- 238000002619 cancer immunotherapy Methods 0.000 description 3
- 125000002837 carbocyclic group Chemical group 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 229940125782 compound 2 Drugs 0.000 description 3
- 229940125898 compound 5 Drugs 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 125000006001 difluoroethyl group Chemical group 0.000 description 3
- 239000003937 drug carrier Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 229920000159 gelatin Polymers 0.000 description 3
- 239000008273 gelatin Substances 0.000 description 3
- 235000019322 gelatine Nutrition 0.000 description 3
- 235000011852 gelatine desserts Nutrition 0.000 description 3
- 125000005843 halogen group Chemical group 0.000 description 3
- 238000004128 high performance liquid chromatography Methods 0.000 description 3
- 229930195733 hydrocarbon Natural products 0.000 description 3
- ZCSHNCUQKCANBX-UHFFFAOYSA-N lithium diisopropylamide Chemical compound [Li+].CC(C)[N-]C(C)C ZCSHNCUQKCANBX-UHFFFAOYSA-N 0.000 description 3
- 125000002757 morpholinyl group Chemical group 0.000 description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 3
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- USPWKWBDZOARPV-UHFFFAOYSA-N pyrazolidine Chemical compound C1CNNC1 USPWKWBDZOARPV-UHFFFAOYSA-N 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000004094 surface-active agent Substances 0.000 description 3
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 3
- QAEDZJGFFMLHHQ-UHFFFAOYSA-N trifluoroacetic anhydride Chemical compound FC(F)(F)C(=O)OC(=O)C(F)(F)F QAEDZJGFFMLHHQ-UHFFFAOYSA-N 0.000 description 3
- 230000004614 tumor growth Effects 0.000 description 3
- QOWBXWFYRXSBAS-UHFFFAOYSA-N (2,4-dimethoxyphenyl)methanamine Chemical compound COC1=CC=C(CN)C(OC)=C1 QOWBXWFYRXSBAS-UHFFFAOYSA-N 0.000 description 2
- JABSMKPYEZTJTE-UHFFFAOYSA-N 1,1-dioxothian-4-ol Chemical compound OC1CCS(=O)(=O)CC1 JABSMKPYEZTJTE-UHFFFAOYSA-N 0.000 description 2
- PAAZPARNPHGIKF-UHFFFAOYSA-N 1,2-dibromoethane Chemical compound BrCCBr PAAZPARNPHGIKF-UHFFFAOYSA-N 0.000 description 2
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 2
- NDOVLWQBFFJETK-UHFFFAOYSA-N 1,4-thiazinane 1,1-dioxide Chemical compound O=S1(=O)CCNCC1 NDOVLWQBFFJETK-UHFFFAOYSA-N 0.000 description 2
- PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 2
- YZUPZGFPHUVJKC-UHFFFAOYSA-N 1-bromo-2-methoxyethane Chemical compound COCCBr YZUPZGFPHUVJKC-UHFFFAOYSA-N 0.000 description 2
- FXHRAKUEZPSMLJ-UHFFFAOYSA-N 1-methyl-1,4-diazepane Chemical compound CN1CCCNCC1 FXHRAKUEZPSMLJ-UHFFFAOYSA-N 0.000 description 2
- BAUWRHPMUVYFOD-UHFFFAOYSA-N 1-methylpiperidin-4-ol Chemical compound CN1CCC(O)CC1 BAUWRHPMUVYFOD-UHFFFAOYSA-N 0.000 description 2
- GIKMWFAAEIACRF-UHFFFAOYSA-N 2,4,5-trichloropyrimidine Chemical compound ClC1=NC=C(Cl)C(Cl)=N1 GIKMWFAAEIACRF-UHFFFAOYSA-N 0.000 description 2
- IDRUEHMBFUJKAK-UHFFFAOYSA-N 2,4-dichloro-5-(trifluoromethyl)pyrimidine Chemical compound FC(F)(F)C1=CN=C(Cl)N=C1Cl IDRUEHMBFUJKAK-UHFFFAOYSA-N 0.000 description 2
- KKSKKVUKDFJQMS-UHFFFAOYSA-N 2,4-dichloro-5-cyclopropylpyrimidine Chemical compound ClC1=NC(Cl)=NC=C1C1CC1 KKSKKVUKDFJQMS-UHFFFAOYSA-N 0.000 description 2
- YFYFVWTWMBQHOH-UHFFFAOYSA-N 2,4-dichloro-5-ethylpyrimidine Chemical compound CCC1=CN=C(Cl)N=C1Cl YFYFVWTWMBQHOH-UHFFFAOYSA-N 0.000 description 2
- ZTHHRSBDBPCCMZ-UHFFFAOYSA-N 2,4-dichloro-5-methoxypyrimidine Chemical compound COC1=CN=C(Cl)N=C1Cl ZTHHRSBDBPCCMZ-UHFFFAOYSA-N 0.000 description 2
- DQXNTSXKIUZJJS-UHFFFAOYSA-N 2,4-dichloro-5-methylpyrimidine Chemical compound CC1=CN=C(Cl)N=C1Cl DQXNTSXKIUZJJS-UHFFFAOYSA-N 0.000 description 2
- INUSQTPGSHFGHM-UHFFFAOYSA-N 2,4-dichloro-5-nitropyrimidine Chemical compound [O-][N+](=O)C1=CN=C(Cl)N=C1Cl INUSQTPGSHFGHM-UHFFFAOYSA-N 0.000 description 2
- BTTNYQZNBZNDOR-UHFFFAOYSA-N 2,4-dichloropyrimidine Chemical compound ClC1=CC=NC(Cl)=N1 BTTNYQZNBZNDOR-UHFFFAOYSA-N 0.000 description 2
- KMHSUNDEGHRBNV-UHFFFAOYSA-N 2,4-dichloropyrimidine-5-carbonitrile Chemical compound ClC1=NC=C(C#N)C(Cl)=N1 KMHSUNDEGHRBNV-UHFFFAOYSA-N 0.000 description 2
- QHTUMQYGZQYEOZ-UHFFFAOYSA-N 2-(4-methylpiperazin-1-yl)ethanol Chemical compound CN1CCN(CCO)CC1 QHTUMQYGZQYEOZ-UHFFFAOYSA-N 0.000 description 2
- KKFDCBRMNNSAAW-UHFFFAOYSA-N 2-(morpholin-4-yl)ethanol Chemical compound OCCN1CCOCC1 KKFDCBRMNNSAAW-UHFFFAOYSA-N 0.000 description 2
- KZTWONRVIPPDKH-UHFFFAOYSA-N 2-(piperidin-1-yl)ethanol Chemical compound OCCN1CCCCC1 KZTWONRVIPPDKH-UHFFFAOYSA-N 0.000 description 2
- LDLCZOVUSADOIV-UHFFFAOYSA-N 2-bromoethanol Chemical compound OCCBr LDLCZOVUSADOIV-UHFFFAOYSA-N 0.000 description 2
- JBKINHFZTVLNEM-UHFFFAOYSA-N 2-bromoethoxy-tert-butyl-dimethylsilane Chemical compound CC(C)(C)[Si](C)(C)OCCBr JBKINHFZTVLNEM-UHFFFAOYSA-N 0.000 description 2
- 125000004200 2-methoxyethyl group Chemical group [H]C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 2
- RSEBUVRVKCANEP-UHFFFAOYSA-N 2-pyrroline Chemical compound C1CC=CN1 RSEBUVRVKCANEP-UHFFFAOYSA-N 0.000 description 2
- MGADZUXDNSDTHW-UHFFFAOYSA-N 2H-pyran Chemical compound C1OC=CC=C1 MGADZUXDNSDTHW-UHFFFAOYSA-N 0.000 description 2
- DPGSPRJLAZGUBQ-UHFFFAOYSA-N 4,4,5,5-tetramethyl-2-vinyl-1,3,2-dioxaborolane Substances CC1(C)OB(C=C)OC1(C)C DPGSPRJLAZGUBQ-UHFFFAOYSA-N 0.000 description 2
- ZEYSHALLPAKUHG-UHFFFAOYSA-N 4-methoxypiperidine Chemical compound COC1CCNCC1 ZEYSHALLPAKUHG-UHFFFAOYSA-N 0.000 description 2
- WTZYTQJELOHMMJ-UHFFFAOYSA-N 5-methyl-4-nitro-1h-pyrazole Chemical compound CC=1NN=CC=1[N+]([O-])=O WTZYTQJELOHMMJ-UHFFFAOYSA-N 0.000 description 2
- YLKFDRWBZAALPN-UHFFFAOYSA-N 6-nitroquinoxaline Chemical compound N1=CC=NC2=CC([N+](=O)[O-])=CC=C21 YLKFDRWBZAALPN-UHFFFAOYSA-N 0.000 description 2
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
- 239000005695 Ammonium acetate Substances 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- HTJDQJBWANPRPF-UHFFFAOYSA-N Cyclopropylamine Chemical compound NC1CC1 HTJDQJBWANPRPF-UHFFFAOYSA-N 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 229930091371 Fructose Natural products 0.000 description 2
- 239000005715 Fructose Substances 0.000 description 2
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 2
- 102000000588 Interleukin-2 Human genes 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- QZRGKCOWNLSUDK-UHFFFAOYSA-N Iodochlorine Chemical compound ICl QZRGKCOWNLSUDK-UHFFFAOYSA-N 0.000 description 2
- 102100034709 Lymphocyte cytosolic protein 2 Human genes 0.000 description 2
- 101710195102 Lymphocyte cytosolic protein 2 Proteins 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000008052 alkyl sulfonates Chemical class 0.000 description 2
- 235000019257 ammonium acetate Nutrition 0.000 description 2
- 229940043376 ammonium acetate Drugs 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 150000001450 anions Chemical class 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 125000005228 aryl sulfonate group Chemical group 0.000 description 2
- GMWFCJXSQQHBPI-UHFFFAOYSA-N azetidin-3-ol Chemical compound OC1CNC1 GMWFCJXSQQHBPI-UHFFFAOYSA-N 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- UENWRTRMUIOCKN-UHFFFAOYSA-N benzyl thiol Chemical compound SCC1=CC=CC=C1 UENWRTRMUIOCKN-UHFFFAOYSA-N 0.000 description 2
- LKXYJYDRLBPHRS-UHFFFAOYSA-N bromocyclopropane Chemical compound BrC1CC1 LKXYJYDRLBPHRS-UHFFFAOYSA-N 0.000 description 2
- 239000007958 cherry flavor Substances 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 229940099112 cornstarch Drugs 0.000 description 2
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 2
- PFWWSGFPICCWGU-UHFFFAOYSA-N cyclopropanesulfonyl chloride Chemical compound ClS(=O)(=O)C1CC1 PFWWSGFPICCWGU-UHFFFAOYSA-N 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 235000014113 dietary fatty acids Nutrition 0.000 description 2
- WQAWEUZTDVWTDB-UHFFFAOYSA-N dimethyl(oxo)phosphanium Chemical compound C[P+](C)=O WQAWEUZTDVWTDB-UHFFFAOYSA-N 0.000 description 2
- XEYBRNLFEZDVAW-ARSRFYASSA-N dinoprostone Chemical compound CCCCC[C@H](O)\C=C\[C@H]1[C@H](O)CC(=O)[C@@H]1C\C=C/CCCC(O)=O XEYBRNLFEZDVAW-ARSRFYASSA-N 0.000 description 2
- 229960002986 dinoprostone Drugs 0.000 description 2
- SXZIXHOMFPUIRK-UHFFFAOYSA-N diphenylmethanimine Chemical compound C=1C=CC=CC=1C(=N)C1=CC=CC=C1 SXZIXHOMFPUIRK-UHFFFAOYSA-N 0.000 description 2
- FRYHCSODNHYDPU-UHFFFAOYSA-N ethanesulfonyl chloride Chemical compound CCS(Cl)(=O)=O FRYHCSODNHYDPU-UHFFFAOYSA-N 0.000 description 2
- 239000000194 fatty acid Substances 0.000 description 2
- 229930195729 fatty acid Natural products 0.000 description 2
- 235000003599 food sweetener Nutrition 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 125000002541 furyl group Chemical group 0.000 description 2
- VHHHONWQHHHLTI-UHFFFAOYSA-N hexachloroethane Chemical compound ClC(Cl)(Cl)C(Cl)(Cl)Cl VHHHONWQHHHLTI-UHFFFAOYSA-N 0.000 description 2
- MTNDZQHUAFNZQY-UHFFFAOYSA-N imidazoline Chemical compound C1CN=CN1 MTNDZQHUAFNZQY-UHFFFAOYSA-N 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 210000002865 immune cell Anatomy 0.000 description 2
- 230000009851 immunogenic response Effects 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000002401 inhibitory effect Effects 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- JJWLVOIRVHMVIS-UHFFFAOYSA-N isopropylamine Chemical compound CC(C)N JJWLVOIRVHMVIS-UHFFFAOYSA-N 0.000 description 2
- 125000001786 isothiazolyl group Chemical group 0.000 description 2
- 125000000842 isoxazolyl group Chemical group 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 239000004005 microsphere Substances 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- YFJAIURZMRJPDB-UHFFFAOYSA-N n,n-dimethylpiperidin-4-amine Chemical compound CN(C)C1CCNCC1 YFJAIURZMRJPDB-UHFFFAOYSA-N 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- LMYJGUNNJIDROI-UHFFFAOYSA-N oxan-4-ol Chemical compound OC1CCOCC1 LMYJGUNNJIDROI-UHFFFAOYSA-N 0.000 description 2
- YSNVSVCWTBLLRW-UHFFFAOYSA-N oxan-4-ylmethanol Chemical compound OCC1CCOCC1 YSNVSVCWTBLLRW-UHFFFAOYSA-N 0.000 description 2
- 125000002971 oxazolyl group Chemical group 0.000 description 2
- 125000005429 oxyalkyl group Chemical group 0.000 description 2
- 230000036961 partial effect Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- HDOWRFHMPULYOA-UHFFFAOYSA-N piperidin-4-ol Chemical compound OC1CCNCC1 HDOWRFHMPULYOA-UHFFFAOYSA-N 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000003449 preventive effect Effects 0.000 description 2
- KJRCEJOSASVSRA-UHFFFAOYSA-N propane-2-thiol Chemical compound CC(C)S KJRCEJOSASVSRA-UHFFFAOYSA-N 0.000 description 2
- WGYKZJWCGVVSQN-UHFFFAOYSA-N propylamine Chemical compound CCCN WGYKZJWCGVVSQN-UHFFFAOYSA-N 0.000 description 2
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 2
- XEYBRNLFEZDVAW-UHFFFAOYSA-N prostaglandin E2 Natural products CCCCCC(O)C=CC1C(O)CC(=O)C1CC=CCCCC(O)=O XEYBRNLFEZDVAW-UHFFFAOYSA-N 0.000 description 2
- DNXIASIHZYFFRO-UHFFFAOYSA-N pyrazoline Chemical compound C1CN=NC1 DNXIASIHZYFFRO-UHFFFAOYSA-N 0.000 description 2
- 125000003226 pyrazolyl group Chemical group 0.000 description 2
- ZVJHJDDKYZXRJI-UHFFFAOYSA-N pyrroline Natural products C1CC=NC1 ZVJHJDDKYZXRJI-UHFFFAOYSA-N 0.000 description 2
- 125000000168 pyrrolyl group Chemical group 0.000 description 2
- MSGRFBKVMUKEGZ-UHFFFAOYSA-N quinoxalin-6-amine Chemical compound N1=CC=NC2=CC(N)=CC=C21 MSGRFBKVMUKEGZ-UHFFFAOYSA-N 0.000 description 2
- XSCHRSMBECNVNS-UHFFFAOYSA-N quinoxaline Chemical compound N1=CC=NC2=CC=CC=C21 XSCHRSMBECNVNS-UHFFFAOYSA-N 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 150000003384 small molecules Chemical class 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical class O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 2
- CQSFZPDGBPHCHV-UHFFFAOYSA-M sodium;cyclopropanesulfinate Chemical compound [Na+].[O-]S(=O)C1CC1 CQSFZPDGBPHCHV-UHFFFAOYSA-M 0.000 description 2
- QJDUDPQVDAASMV-UHFFFAOYSA-M sodium;ethanethiolate Chemical compound [Na+].CC[S-] QJDUDPQVDAASMV-UHFFFAOYSA-M 0.000 description 2
- LYPGDCWPTHTUDO-UHFFFAOYSA-M sodium;methanesulfinate Chemical compound [Na+].CS([O-])=O LYPGDCWPTHTUDO-UHFFFAOYSA-M 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 239000012730 sustained-release form Substances 0.000 description 2
- 239000003765 sweetening agent Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- HXRDRJKAEYHOBB-UHFFFAOYSA-N tert-butyl 3-(hydroxymethyl)azetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(CO)C1 HXRDRJKAEYHOBB-UHFFFAOYSA-N 0.000 description 2
- APCBTRDHCDOPNY-UHFFFAOYSA-N tert-butyl 3-hydroxypyrrolidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(O)C1 APCBTRDHCDOPNY-UHFFFAOYSA-N 0.000 description 2
- YBNJZIDYXCGAPX-UHFFFAOYSA-N tert-butyl 4-(2-hydroxyethyl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CCO)CC1 YBNJZIDYXCGAPX-UHFFFAOYSA-N 0.000 description 2
- CTEDVGRUGMPBHE-UHFFFAOYSA-N tert-butyl 4-(hydroxymethyl)piperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(CO)CC1 CTEDVGRUGMPBHE-UHFFFAOYSA-N 0.000 description 2
- CRFSWDBNKHNGGA-UHFFFAOYSA-N tert-butyl 4-hydroxyazepane-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCCC(O)CC1 CRFSWDBNKHNGGA-UHFFFAOYSA-N 0.000 description 2
- PWQLFIKTGRINFF-UHFFFAOYSA-N tert-butyl 4-hydroxypiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(O)CC1 PWQLFIKTGRINFF-UHFFFAOYSA-N 0.000 description 2
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- OIBKBVFFZYCBAQ-UHFFFAOYSA-N tert-butyl n-(5-bromo-1,3-thiazol-2-yl)carbamate Chemical compound CC(C)(C)OC(=O)NC1=NC=C(Br)S1 OIBKBVFFZYCBAQ-UHFFFAOYSA-N 0.000 description 2
- NEMXVXVJGXZDRR-UHFFFAOYSA-N tert-butyl n-(azetidin-3-yl)carbamate Chemical compound CC(C)(C)OC(=O)NC1CNC1 NEMXVXVJGXZDRR-UHFFFAOYSA-N 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- CBDKQYKMCICBOF-UHFFFAOYSA-N thiazoline Chemical compound C1CN=CS1 CBDKQYKMCICBOF-UHFFFAOYSA-N 0.000 description 2
- 125000000335 thiazolyl group Chemical group 0.000 description 2
- 125000001544 thienyl group Chemical group 0.000 description 2
- BRNULMACUQOKMR-UHFFFAOYSA-N thiomorpholine Chemical compound C1CSCCN1 BRNULMACUQOKMR-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- URAYPUMNDPQOKB-UHFFFAOYSA-N triacetin Chemical compound CC(=O)OCC(OC(C)=O)COC(C)=O URAYPUMNDPQOKB-UHFFFAOYSA-N 0.000 description 2
- GRGCWBWNLSTIEN-UHFFFAOYSA-N trifluoromethanesulfonyl chloride Chemical compound FC(F)(F)S(Cl)(=O)=O GRGCWBWNLSTIEN-UHFFFAOYSA-N 0.000 description 2
- 210000004881 tumor cell Anatomy 0.000 description 2
- 235000015112 vegetable and seed oil Nutrition 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- PEAKMPWXINHZSO-UHFFFAOYSA-N (1-methyl-3,6-dihydro-2h-pyridin-4-yl)boronic acid Chemical compound CN1CCC(B(O)O)=CC1 PEAKMPWXINHZSO-UHFFFAOYSA-N 0.000 description 1
- 125000002733 (C1-C6) fluoroalkyl group Chemical group 0.000 description 1
- KZPYGQFFRCFCPP-UHFFFAOYSA-N 1,1'-bis(diphenylphosphino)ferrocene Chemical compound [Fe+2].C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=C[C-]1P(C=1C=CC=CC=1)C1=CC=CC=C1 KZPYGQFFRCFCPP-UHFFFAOYSA-N 0.000 description 1
- 125000001399 1,2,3-triazolyl group Chemical group N1N=NC(=C1)* 0.000 description 1
- WNXJIVFYUVYPPR-UHFFFAOYSA-N 1,3-dioxolane Chemical compound C1COCO1 WNXJIVFYUVYPPR-UHFFFAOYSA-N 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- HPARLNRMYDSBNO-UHFFFAOYSA-N 1,4-benzodioxine Chemical compound C1=CC=C2OC=COC2=C1 HPARLNRMYDSBNO-UHFFFAOYSA-N 0.000 description 1
- JKTCBAGSMQIFNL-UHFFFAOYSA-N 2,3-dihydrofuran Chemical compound C1CC=CO1 JKTCBAGSMQIFNL-UHFFFAOYSA-N 0.000 description 1
- HZFCUISVOSWUEF-UHFFFAOYSA-N 2,3-dihydrofuran;oxolane Chemical compound C1CCOC1.C1CC=CO1 HZFCUISVOSWUEF-UHFFFAOYSA-N 0.000 description 1
- WHPFEQUEHBULBW-UHFFFAOYSA-N 2,4-dichloro-5-fluoropyrimidine Chemical compound FC1=CN=C(Cl)N=C1Cl WHPFEQUEHBULBW-UHFFFAOYSA-N 0.000 description 1
- DOSGEBYQRMBTGS-UHFFFAOYSA-N 2-(3,6-dihydro-2h-pyran-4-yl)-4,4,5,5-tetramethyl-1,3,2-dioxaborolane Chemical compound O1C(C)(C)C(C)(C)OB1C1=CCOCC1 DOSGEBYQRMBTGS-UHFFFAOYSA-N 0.000 description 1
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
- KPGXRSRHYNQIFN-UHFFFAOYSA-L 2-oxoglutarate(2-) Chemical compound [O-]C(=O)CCC(=O)C([O-])=O KPGXRSRHYNQIFN-UHFFFAOYSA-L 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- XKTYXVDYIKIYJP-UHFFFAOYSA-N 3h-dioxole Chemical compound C1OOC=C1 XKTYXVDYIKIYJP-UHFFFAOYSA-N 0.000 description 1
- WNWVKZTYMQWFHE-UHFFFAOYSA-N 4-ethylmorpholine Chemical group [CH2]CN1CCOCC1 WNWVKZTYMQWFHE-UHFFFAOYSA-N 0.000 description 1
- 125000004487 4-tetrahydropyranyl group Chemical group [H]C1([H])OC([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 206010061424 Anal cancer Diseases 0.000 description 1
- 244000099147 Ananas comosus Species 0.000 description 1
- 235000007119 Ananas comosus Nutrition 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000167854 Bourreria succulenta Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
- 201000009030 Carcinoma Diseases 0.000 description 1
- 208000017897 Carcinoma of esophagus Diseases 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 1
- 239000007995 HEPES buffer Substances 0.000 description 1
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 1
- 101000800483 Homo sapiens Toll-like receptor 8 Proteins 0.000 description 1
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 206010027476 Metastases Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-M Methanesulfonate Chemical group CS([O-])(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 241000238367 Mya arenaria Species 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 229910002651 NO3 Inorganic materials 0.000 description 1
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 1
- NHNBFGGVMKEFGY-UHFFFAOYSA-N Nitrate Chemical compound [O-][N+]([O-])=O NHNBFGGVMKEFGY-UHFFFAOYSA-N 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 101150003085 Pdcl gene Proteins 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 description 1
- 102000001253 Protein Kinase Human genes 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 229920001800 Shellac Polymers 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 230000037453 T cell priming Effects 0.000 description 1
- 102000008235 Toll-Like Receptor 9 Human genes 0.000 description 1
- 108010060818 Toll-Like Receptor 9 Proteins 0.000 description 1
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 1
- 102100033110 Toll-like receptor 8 Human genes 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- PNEYBMLMFCGWSK-UHFFFAOYSA-N aluminium oxide Inorganic materials [O-2].[O-2].[O-2].[Al+3].[Al+3] PNEYBMLMFCGWSK-UHFFFAOYSA-N 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 230000030741 antigen processing and presentation Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 239000004599 antimicrobial Substances 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 229940072107 ascorbate Drugs 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229940077388 benzenesulfonate Drugs 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-M benzenesulfonate Chemical group [O-]S(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-M 0.000 description 1
- 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 description 1
- 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 125000004619 benzopyranyl group Chemical group O1C(C=CC2=C1C=CC=C2)* 0.000 description 1
- 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 description 1
- 210000003445 biliary tract Anatomy 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 210000000601 blood cell Anatomy 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 235000019693 cherries Nutrition 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 229940001468 citrate Drugs 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 229940125904 compound 1 Drugs 0.000 description 1
- 229940126214 compound 3 Drugs 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000016396 cytokine production Effects 0.000 description 1
- 230000001461 cytolytic effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000002950 deficient Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- VLCINIKIVYNLPT-UHFFFAOYSA-J dicalcium;hydrogen phosphate Chemical compound [Ca+2].[Ca+2].OP(O)([O-])=O.[O-]P([O-])([O-])=O VLCINIKIVYNLPT-UHFFFAOYSA-J 0.000 description 1
- UGMCXQCYOVCMTB-UHFFFAOYSA-K dihydroxy(stearato)aluminium Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[Al](O)O UGMCXQCYOVCMTB-UHFFFAOYSA-K 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 238000007876 drug discovery Methods 0.000 description 1
- 239000012636 effector Substances 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- 238000011067 equilibration Methods 0.000 description 1
- 210000003238 esophagus Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 150000002191 fatty alcohols Chemical class 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 125000003709 fluoroalkyl group Chemical group 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 229940050411 fumarate Drugs 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 102000034356 gene-regulatory proteins Human genes 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 125000005456 glyceride group Chemical group 0.000 description 1
- 239000001087 glyceryl triacetate Substances 0.000 description 1
- 235000013773 glyceryl triacetate Nutrition 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 125000004051 hexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 230000001506 immunosuppresive effect Effects 0.000 description 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 239000007972 injectable composition Substances 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 239000011147 inorganic material Substances 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 238000005040 ion trap Methods 0.000 description 1
- 238000000534 ion trap mass spectrometry Methods 0.000 description 1
- 150000002500 ions Chemical class 0.000 description 1
- GWVMLCQWXVFZCN-UHFFFAOYSA-N isoindoline Chemical compound C1=CC=C2CNCC2=C1 GWVMLCQWXVFZCN-UHFFFAOYSA-N 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 229940043355 kinase inhibitor Drugs 0.000 description 1
- 239000003041 laboratory chemical Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 210000002540 macrophage Anatomy 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000004949 mass spectrometry Methods 0.000 description 1
- 238000001819 mass spectrum Methods 0.000 description 1
- 230000035800 maturation Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 230000009401 metastasis Effects 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 125000004170 methylsulfonyl group Chemical group [H]C([H])([H])S(*)(=O)=O 0.000 description 1
- JYGWVCOFTZZSGS-UHFFFAOYSA-N methylsulfonylmethanamine Chemical compound CS(=O)(=O)CN JYGWVCOFTZZSGS-UHFFFAOYSA-N 0.000 description 1
- 239000000693 micelle Substances 0.000 description 1
- 239000003094 microcapsule Substances 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 239000011859 microparticle Substances 0.000 description 1
- 230000005012 migration Effects 0.000 description 1
- 238000013508 migration Methods 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000003032 molecular docking Methods 0.000 description 1
- AVAWMINJNRAQFS-UHFFFAOYSA-N n,n-dimethylpyrrolidin-3-amine Chemical compound CN(C)C1CCNC1 AVAWMINJNRAQFS-UHFFFAOYSA-N 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000007908 nanoemulsion Substances 0.000 description 1
- 239000002077 nanosphere Substances 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 239000002353 niosome Substances 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 239000007968 orange flavor Substances 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- LXCFILQKKLGQFO-UHFFFAOYSA-N p-hydroxybenzoic acid methyl ester Natural products COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000006072 paste Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 239000008024 pharmaceutical diluent Substances 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 229960003742 phenol Drugs 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001592 potato starch Polymers 0.000 description 1
- 229940116317 potato starch Drugs 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000035755 proliferation Effects 0.000 description 1
- 230000002035 prolonged effect Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 108060006633 protein kinase Proteins 0.000 description 1
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- JHHZLHWJQPUNKB-UHFFFAOYSA-N pyrrolidin-3-ol Chemical compound OC1CCNC1 JHHZLHWJQPUNKB-UHFFFAOYSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000021821 regulation of B cell proliferation Effects 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000004208 shellac Substances 0.000 description 1
- ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
- 229940113147 shellac Drugs 0.000 description 1
- 235000013874 shellac Nutrition 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000007892 solid unit dosage form Substances 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 229940086735 succinate Drugs 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- RLHMCXQTIPFLRQ-UHFFFAOYSA-N tert-butyl 3-hydroxy-2-methylpyrrolidine-1-carboxylate Chemical compound CC1C(O)CCN1C(=O)OC(C)(C)C RLHMCXQTIPFLRQ-UHFFFAOYSA-N 0.000 description 1
- XRRXRQJQQKMFBC-UHFFFAOYSA-N tert-butyl 3-hydroxyazetidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CC(O)C1 XRRXRQJQQKMFBC-UHFFFAOYSA-N 0.000 description 1
- VRXIOAYUQIITBU-UHFFFAOYSA-N tert-butyl 4-(2-hydroxyethyl)piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCN(CCO)CC1 VRXIOAYUQIITBU-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 125000003554 tetrahydropyrrolyl group Chemical group 0.000 description 1
- 125000004632 tetrahydrothiopyranyl group Chemical group S1C(CCCC1)* 0.000 description 1
- CZDYPVPMEAXLPK-UHFFFAOYSA-N tetramethylsilane Chemical group C[Si](C)(C)C CZDYPVPMEAXLPK-UHFFFAOYSA-N 0.000 description 1
- YODQQARABJQLIP-UHFFFAOYSA-N thian-4-ol Chemical compound OC1CCSCC1 YODQQARABJQLIP-UHFFFAOYSA-N 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229940033663 thimerosal Drugs 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- 229960002622 triacetin Drugs 0.000 description 1
- 125000004044 trifluoroacetyl group Chemical group FC(C(=O)*)(F)F 0.000 description 1
- 230000005740 tumor formation Effects 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 235000012431 wafers Nutrition 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000009637 wintergreen oil Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
Definitions
- the invention relates to the field of medicinal chemistry, in particular to an HPK1 kinase regulator, a preparation method and application thereof.
- HPK1 hematopoietic progenitor kinase 1
- HPK1 belongs to the MAP4K family and is mainly distributed in blood cells, such as T cells, B cells, macrophages, dendritic cells, and neutrophils.
- HPK1 is involved in the regulation of various immune cell signaling pathways, and is a negative regulator of T cell receptor (TCR)-mediated signaling pathways.
- TCR T cell receptor
- TCR T cell receptor
- HPK1 in the cytoplasm is recruited to the plasma membrane, and the activated HPK1 phosphorylates the adaptor protein SLP76, thereby activating SLP76 as a docking site for the negative regulatory protein 14-3-3p, and finally disrupting the TCR signaling complex stability (Hernandez et al Cell Rep. 2018 25:80).
- Prostaglandin E2 can cause T cells to not efficiently produce cytokines such as IL-2, and to not proliferate normally and then undergo apoptosis. These phenomena can be reversed by knocking down HPK1. Moreover, in a mouse model, HPK1 knockout T cells can significantly inhibit the formation of Lewis lung cancer (Alzabin S. et al. Cancer Immunol. Immunother. 2010, 59:419). In addition, both in vitro and in vivo models, HPK1-deficient dendritic cells can more efficiently present antigens (Alzabin S. et al., J Immunol. 2009, 182:6187).
- the present invention provides compounds shown below:
- One object of the present invention is to provide a class of compounds or stereoisomers thereof, prodrugs thereof, pharmaceutically acceptable salts thereof, or pharmaceutically acceptable solvates thereof, which have the activity of modulating HPK1.
- Another object of the present invention is to provide a preparation method of the above compound.
- Another object of the present invention is to provide a pharmaceutical composition comprising the above-mentioned compound.
- Another object of the present invention is to provide the use of the above-mentioned compounds or pharmaceutical compositions comprising the above-mentioned compounds in cancer immunotherapy.
- Another object of the present invention is to provide the use of the above-mentioned compound or a pharmaceutical composition comprising the above-mentioned compound in the preparation of a medicament for the prevention and/or treatment of cancer or other diseases.
- Another object of the present invention is to provide a method of treating cancer comprising administering to a subject an effective amount of a compound of the present invention or a composition comprising the same.
- the present invention is achieved through the following technical solutions.
- the present invention provides compounds of the following general formula:
- R 1 is selected from and R 1 is not hydrogen
- Each L is independently selected from direct bond, C1-C6 alkylene
- Each Y is independently selected from hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, R a R b N-C1-C6 alkyl, HO-C1-C6 alkyl;
- Each Z is independently selected from hydrogen, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl, C3-C6 cycloalkyl-O-, HO-C1-C6 alkyl, R a R b N-, R a R b N-C1-C6 alkyl;
- R a , R b are each independently selected from hydrogen, C1-C6 alkyl
- X 1 , X 2 , X 3 , and X 4 are each independently selected from C, CH, CH 2 , N, NH, O, S;
- Y 1 , Y 2 , Y 3 , Y 4 are each independently selected from C, CH, CH 2 , N, NH, O, S;
- R 2 is selected from:
- Z 1 and Z 2 are each independently selected from C1-C6 alkyl, C3-C8 cycloalkyl;
- Z 3 and Z 4 are each independently selected from hydrogen, C1-C6 alkyl, halogenated C1-C6 alkyl, C3-C6 cycloalkyl, halogenated C3-C6 cycloalkyl, and Z 4 is not hydrogen ;
- Z 5 is selected from C1-C6 alkyl, halogenated C1-C6 alkyl, C3-C8 cycloalkyl, C1-C6 heteroatom-containing alkyl, C3-C8 heteroatom-containing cycloalkyl;
- Z 6 and Z 7 are each independently selected from hydrogen, C1-C6 alkyl, halogenated C1-C6 alkyl, C3-C6 cycloalkyl, halogenated C3-C6 cycloalkyl, or Z 6 , Z 7 together with the N atoms to which they are commonly attached to form a substituted or unsubstituted 4-8 membered heterocycle containing 1 to 2 heteroatoms, the substituents being selected from halogen, C1-C6 alkyl, C3-C8 cycloalkyl ;
- R is selected from hydrogen, halogen, halogenated C1-C6 alkyl (eg, trifluoromethyl), cyano, nitro, C1-C6 alkyl (eg, methyl, ethyl), C1-C6 alkoxy group (eg, methoxy), C3-C6 cycloalkyl (eg, cyclopropyl), C2-C6 alkenyl (eg, vinyl);
- R 4 and R 5 are each independently selected from hydrogen, fluorine, chlorine, bromine, iodine, C1-C6 alkyl, and R 4 and R 5 are not hydrogen at the same time.
- each L is independently selected from a direct bond, methylene, ethylene.
- each Z is independently selected from hydrogen, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, R a R b N-.
- each Z is independently selected from hydrogen, hydroxy, C1-C6 alkoxy, R a R b N-.
- each Y is independently selected from hydrogen, methyl, ethyl, isopropyl, cyclopropyl, 2-hydroxyethyl, 2-(N,N-dimethylamino)ethyl.
- each Z is independently selected from hydrogen, hydroxy, amino, N,N-dimethylamino, methoxy.
- R a , R b are each independently selected from H, methyl.
- X 1 , X 2 , X 3 , X 4 are each independently selected from C, CH, N, O, S.
- X 1 , X 2 , X 3 , X 4 are each independently selected from C, CH, N, S.
- Y 1 , Y 2 , Y 3 , Y 4 are each independently selected from C, CH, N, O, S.
- Y 1 , Y 2 , Y 3 , Y 4 are each independently selected from C, CH, N.
- Z 1 , Z 2 are each independently selected from C1-C6 alkyl.
- Z 1 , Z 2 are methyl groups.
- Z 3 , Z 4 are each independently selected from hydrogen, C1-C6 alkyl, haloC1-C6 alkyl, C3-C6 cycloalkyl, and Z 4 is not hydrogen.
- Z3, Z4 are each independently selected from hydrogen, methyl, ethyl, isopropyl, cyclopropyl, -CF3 , and Z4 is not hydrogen.
- Z 3 is selected from hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl.
- Z 4 is selected from C1-C6 alkyl, halogenated C1-C6 alkyl, C3-C6 cycloalkyl.
- Z3 is selected from hydrogen, methyl, ethyl, cyclopropyl.
- Z4 is selected from methyl, ethyl, isopropyl, -CF3 , cyclopropyl.
- Z 5 is selected from C1-C6 alkyl, C3-C6 cycloalkyl.
- Z5 is selected from methyl, ethyl, isopropyl, cyclopropyl.
- Z 6 , Z 7 are each independently selected from hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl.
- Z 6 , Z 7 are each independently selected from hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, and Z 6 , Z 7 are not both hydrogen.
- Z 6 , Z 7 are each independently selected from hydrogen, methyl, ethyl, isopropyl, cyclopropyl, and Z 6 , Z 7 are not both hydrogen.
- Z 6 , Z 7 are formed together with the N atom to which they are commonly attached (preferably ).
- Z6 is hydrogen, methyl; Z7 is selected from methyl, ethyl, isopropyl, cyclopropyl; or, Z6 , Z7 are formed together with the N atom to which they are commonly attached
- R3 is selected from hydrogen, fluorine, chlorine, bromine, trifluoromethyl, cyano, nitro, methyl, ethyl, methoxy, cyclopropyl, vinyl.
- R 4 , R 5 are each independently selected from hydrogen, fluoro, chloro, methyl, and R 4 , R 5 are not both hydrogen.
- R4 is selected from hydrogen, fluorine, chlorine, methyl
- R5 is selected from hydrogen, methyl
- R4 , R5 are not both hydrogen.
- the present invention provides a compound of the general formula represented by formula (I), or a stereoisomer of the compound, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable compound thereof solvates,
- Z 1 and Z 2 are each independently selected from C1-C6 alkyl, C3-C8 cycloalkyl;
- R 1 is selected from and R 1 is not hydrogen
- Each L is independently selected from direct bond, C1-C6 alkylene
- Each Y is independently selected from hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, R a R b N-C1-C6 alkyl, HO-C1-C6 alkyl;
- Each Z is independently selected from hydrogen, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl, C3-C6 cycloalkyl-O-, HO-C1-C6 alkyl, R a R b N-, R a R b N-C1-C6 alkyl;
- R a , R b are each independently selected from hydrogen, C1-C6 alkyl
- X 1 , X 2 , X 3 , and X 4 are each independently selected from C, CH, CH 2 , N, NH, O, S;
- Y 1 , Y 2 , Y 3 , Y 4 are each independently selected from C, CH, CH 2 , N, NH, O, S;
- R is selected from hydrogen, halogen, halogenated C1-C6 alkyl (eg, trifluoromethyl), cyano, nitro, C1-C6 alkyl (eg, methyl, ethyl), C1-C6 alkoxy group (eg, methoxy), C3-C6 cycloalkyl (eg, cyclopropyl), C2-C6 alkenyl (eg, vinyl);
- R 4 and R 5 are each independently selected from hydrogen, fluorine, chlorine, bromine, iodine, C1-C6 alkyl, and R 4 and R 5 are not hydrogen at the same time.
- Z 1 , Z 2 are each independently selected from C1-C6 alkyl.
- Z 1 , Z 2 are methyl groups.
- each L is independently selected from a direct bond, methylene, ethylene.
- each Z is independently selected from hydrogen, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, R a R b N-.
- each Z is independently selected from hydrogen, hydroxy, C1-C6 alkoxy, R a R b N-.
- each Y is independently selected from hydrogen, methyl, ethyl, isopropyl, cyclopropyl, 2-hydroxyethyl, 2-(N,N-dimethylamino)ethyl.
- each Z is independently selected from hydrogen, hydroxy, amino, N,N-dimethylamino, methoxy.
- R 1 is When L is selected from direct bond, C1-C6 alkylene, preferably from direct bond, methylene, ethylene; Y is selected from hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, HO-C1 -C6 alkyl, R a R b N-C1-C6 alkyl, preferably selected from hydrogen, methyl, ethyl, isopropyl, cyclopropyl, 2-hydroxyethyl, 2-(N,N-di methylamino)ethyl.
- R 1 is , L is selected from C1-C6 alkylene, preferably ethylene; Z is selected from hydrogen, hydroxyl, C1-C6 alkoxy, R a R b N-, preferably hydrogen, hydroxyl, N,N- Dimethylamino, methoxy.
- R 1 is When L is selected from direct bond, C1-C6 alkylene, preferably from direct bond, methylene, ethylene.
- R 1 is selected from , L is a direct key.
- R 1 is When L is selected from direct bond, C1-C6 alkylene, preferably selected from direct bond, methylene; Y is selected from hydrogen, C1-C6 alkyl, preferably selected from C1-C6 alkyl, or preferably selected from hydrogen , methyl, or more preferably methyl.
- R 1 is , L is selected from direct bond, C1-C6 alkylene, preferably direct bond, methylene; Y is selected from hydrogen, C1-C6 alkyl, preferably hydrogen, methyl.
- R 1 is , L is a direct bond; Y is selected from hydrogen and C1-C6 alkyl, preferably from hydrogen and methyl.
- R 1 is selected from , each L is independently selected from C1-C6 alkylene, preferably ethylene.
- R 1 is , L is selected from C1-C6 alkylene, preferably ethylene; Y is selected from hydrogen, C1-C6 alkyl, preferably hydrogen and methyl.
- R 1 is When L is selected from C1-C6 alkylene, preferably ethylene; Y is selected from hydrogen, C1-C6 alkyl, preferably from C1-C6 alkyl, or preferably from hydrogen, methyl, or more preferably is methyl.
- R 1 is When , L is selected from C1-C6 alkylene, preferably ethylene; Z is selected from hydrogen, hydroxyl, R a R b N-, preferably hydrogen, hydroxyl, N,N-dimethylamino.
- R 1 is When , L is selected from C1-C6 alkylene, preferably ethylene; Z is selected from hydrogen, hydroxyl, R a R b N-, preferably hydrogen, hydroxyl, amino, N,N-dimethylamino.
- R 1 is When L is selected from C1-C6 alkylene, preferably ethylene; Z is selected from hydroxyl, C1-C6 alkoxy, R a R b N-, preferably selected from hydroxyl, methoxy, N,N- Dimethylamino.
- R a , R b are each independently selected from H, methyl.
- X 1 , X 2 , X 3 , X 4 are each independently selected from C, CH, N, O, S.
- X 1 , X 2 , X 3 , X 4 are each independently selected from C, CH, N, S.
- Y 1 , Y 2 , Y 3 , Y 4 are each independently selected from C, CH, N, O, S.
- Y 1 , Y 2 , Y 3 , Y 4 are each independently selected from C, CH, N.
- R3 is selected from hydrogen, halogen, C1-C6 alkyl (eg, methyl, ethyl), C3-C6 cycloalkyl (eg, cyclopropyl), C2-C6 alkenyl (eg, , vinyl).
- R3 is selected from hydrogen, fluoro, chloro, bromo, methyl, ethyl, cyclopropyl, vinyl.
- R 4 , R 5 are each independently selected from hydrogen, fluorine, chlorine, and R 4 , R 5 are not both hydrogen.
- R 4 is chloro and R 5 is hydrogen.
- the present invention provides a compound of the general formula represented by formula (II), or a stereoisomer of the compound, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable compound thereof solvates,
- Z 3 and Z 4 are each independently selected from hydrogen, C1-C6 alkyl, halogenated C1-C6 alkyl, C3-C6 cycloalkyl, halogenated C3-C6 cycloalkyl, and Z 4 is not hydrogen;
- R 1 is selected from and R 1 is not hydrogen
- Each L is independently selected from direct bond, C1-C6 alkylene
- Each Y is independently selected from hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, R a R b N-C1-C6 alkyl, HO-C1-C6 alkyl;
- Each Z is independently selected from hydrogen, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl, C3-C6 cycloalkyl-O-, HO-C1-C6 alkyl, R a R b N-, R a R b N-C1-C6 alkyl;
- R a , R b are each independently selected from hydrogen, C1-C6 alkyl
- X 1 , X 2 , X 3 , and X 4 are each independently selected from C, CH, CH 2 , N, NH, O, S;
- Y 1 , Y 2 , Y 3 , Y 4 are each independently selected from C, CH, CH 2 , N, NH, O, S;
- R is selected from hydrogen, halogen, halogenated C1-C6 alkyl (eg, trifluoromethyl), cyano, nitro, C1-C6 alkyl (eg, methyl, ethyl), C1-C6 alkoxy group (eg, methoxy), C3-C6 cycloalkyl (eg, cyclopropyl), C2-C6 alkenyl (eg, vinyl);
- R 4 and R 5 are each independently selected from hydrogen, fluorine, chlorine, bromine, iodine, C1-C6 alkyl, and R 4 and R 5 are not hydrogen at the same time.
- Z 3 , Z 4 are each independently selected from hydrogen, C1-C6 alkyl, haloC1-C6 alkyl, C3-C6 cycloalkyl, and Z 4 is not hydrogen.
- Z3, Z4 are each independently selected from hydrogen, methyl, ethyl, isopropyl, cyclopropyl, -CF3 , and Z4 is not hydrogen.
- Z 3 is selected from hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl.
- Z 4 is selected from C1-C6 alkyl, halogenated C1-C6 alkyl, C3-C6 cycloalkyl.
- Z3 is selected from hydrogen, methyl, ethyl, cyclopropyl.
- Z4 is selected from methyl, ethyl, isopropyl, -CF3 , cyclopropyl.
- R 1 is selected from and R 1 is not hydrogen.
- each L is independently selected from a direct bond, methylene, ethylene.
- each Z is independently selected from hydrogen, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, R a R b N-.
- each Z is independently selected from hydrogen, hydroxy, C1-C6 alkoxy, R a R b N-.
- each Y is independently selected from hydrogen, methyl, ethyl, isopropyl, cyclopropyl, 2-hydroxyethyl, 2-(N,N-dimethylamino)ethyl.
- each Z is independently selected from hydrogen, hydroxy, amino, N,N-dimethylamino, methoxy.
- R 1 is When L is selected from direct bond, C1-C6 alkylene, preferably from direct bond, methylene, ethylene; Y is selected from hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, HO-C1 -C6 alkyl, R a R b N-C1-C6 alkyl, preferably selected from hydrogen, methyl, ethyl, isopropyl, cyclopropyl, 2-hydroxyethyl, 2-(N,N-di methylamino)ethyl.
- R 1 is , L is selected from C1-C6 alkylene, preferably ethylene; Z is selected from hydrogen, hydroxyl, C1-C6 alkoxy, R a R b N-, preferably hydrogen, hydroxyl, N,N- Dimethylamino, methoxy.
- R 1 is When L is selected from direct bond, C1-C6 alkylene, preferably from direct bond, methylene, ethylene.
- R 1 is selected from , L is a direct key.
- R 1 is selected from , each L is independently selected from a direct bond, a C1-C6 alkylene group, preferably a direct bond, a methylene group; each Y is independently selected from hydrogen, a C1-C6 alkyl group, preferably a C1-C6 alkyl group , or preferably selected from hydrogen, methyl, or more preferably methyl.
- R 1 is , L is a direct bond; Y is selected from hydrogen and C1-C6 alkyl, preferably from hydrogen and methyl.
- R 1 is When L is selected from C1-C6 alkylene, preferably ethylene.
- R 1 is , L is selected from C1-C6 alkylene, preferably ethylene; Y is selected from hydrogen, C1-C6 alkyl, preferably hydrogen and methyl.
- R 1 is When L is selected from C1-C6 alkylene, preferably ethylene; Y is selected from hydrogen, C1-C6 alkyl, preferably from C1-C6 alkyl, or preferably from hydrogen, methyl, or more preferably is methyl.
- R 1 is When , L is selected from C1-C6 alkylene, preferably ethylene; Z is selected from hydrogen, hydroxyl, R a R b N-, preferably hydrogen, hydroxyl, N,N-dimethylamino.
- R 1 is When , L is selected from C1-C6 alkylene, preferably ethylene; Z is selected from hydrogen, hydroxyl, R a R b N-, preferably hydrogen, hydroxyl, amino, N,N-dimethylamino.
- R 1 is selected from , each L is independently selected from C1-C6 alkylene, preferably ethylene; each Z is independently selected from hydrogen, hydroxyl, R a R b N-, preferably hydrogen, hydroxyl, amino, N,N - Dimethylamino.
- R 1 is When L is selected from C1-C6 alkylene, preferably ethylene; Z is selected from hydroxyl, C1-C6 alkoxy, R a R b N-, preferably selected from hydroxyl, methoxy, N,N- Dimethylamino.
- R a , R b are each independently selected from H, methyl.
- X 1 , X 2 , X 3 , X 4 are each independently selected from C, CH, N, O, S.
- X 1 , X 2 , X 3 , X 4 are each independently selected from C, CH, N, S.
- X 1 , X 2 , X 3 , X 4 are each independently selected from CH, N.
- Y 1 , Y 2 , Y 3 , Y 4 are each independently selected from C, CH, N, O, S.
- Y 1 , Y 2 , Y 3 , Y 4 are each independently selected from C, CH, N.
- R 3 is selected from hydrogen, halogen, halogenated C1-C6 alkyl (eg, trifluoromethyl), cyano, nitro, C1-C6 alkyl (eg, methyl), C1- C6 alkoxy (eg, methoxy), C3-C6 cycloalkyl (eg, cyclopropyl).
- R3 is selected from hydrogen, fluoro, chloro, bromo, trifluoromethyl, cyano, nitro, methyl, methoxy, cyclopropyl.
- R 4 , R 5 are each independently selected from hydrogen, fluoro, chloro, methyl, and R 4 , R 5 are not both hydrogen.
- R4 is selected from hydrogen, fluorine, chlorine, methyl
- R5 is selected from H, methyl
- R4 , R5 are not both hydrogen.
- the present invention provides a compound of the general formula represented by formula (III), or a stereoisomer of the compound, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable compound thereof solvates,
- Z 5 is selected from C1-C6 alkyl, halogenated C1-C6 alkyl, C3-C8 cycloalkyl, C1-C6 heteroatom-containing alkyl, C3-C8 heteroatom-containing cycloalkyl;
- R 1 is selected from and R 1 is not hydrogen
- Each L is independently selected from direct bond, C1-C6 alkylene
- Each Y is independently selected from hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, R a R b N-C1-C6 alkyl, HO-C1-C6 alkyl;
- Each Z is independently selected from hydrogen, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl, C3-C6 cycloalkyl-O-, HO-C1-C6 alkyl, R a R b N-, R a R b N-C1-C6 alkyl;
- R a , R b are each independently selected from hydrogen, C1-C6 alkyl
- X 1 , X 2 , X 3 , and X 4 are each independently selected from C, CH, CH 2 , N, NH, O, S;
- Y 1 , Y 2 , Y 3 , Y 4 are each independently selected from C, CH, CH 2 , N, NH, O, S;
- R is selected from hydrogen, halogen, halogenated C1-C6 alkyl (eg, trifluoromethyl), cyano, nitro, C1-C6 alkyl (eg, methyl, ethyl), C1-C6 alkoxy group (eg, methoxy), C3-C6 cycloalkyl (eg, cyclopropyl), C2-C6 alkenyl (eg, vinyl);
- R 4 and R 5 are each independently selected from hydrogen, fluorine, chlorine, bromine, iodine, C1-C6 alkyl, and R 4 and R 5 are not hydrogen at the same time.
- Z 5 is selected from C1-C6 alkyl, C3-C8 cycloalkyl.
- Z 5 is selected from C1-C6 alkyl, C3-C6 cycloalkyl.
- Z5 is selected from methyl, ethyl, isopropyl, cyclopropyl.
- each L is independently selected from a direct bond, methylene, ethylene.
- each Z is independently selected from hydrogen, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, R a R b N-.
- each Z is independently selected from hydrogen, hydroxy, C1-C6 alkoxy, R a R b N-.
- each Y is independently selected from hydrogen, methyl, ethyl, isopropyl, cyclopropyl, 2-hydroxyethyl, 2-(N,N-dimethylamino)ethyl.
- each Z is independently selected from hydrogen, hydroxy, amino, N,N-dimethylamino, methoxy.
- R 1 is When L is selected from direct bond, C1-C6 alkylene, preferably from direct bond, methylene, ethylene; Y is selected from hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, HO-C1 -C6 alkyl, R a R b N-C1-C6 alkyl, preferably selected from hydrogen, methyl, ethyl, isopropyl, cyclopropyl, 2-hydroxyethyl, 2-(N,N-di methylamino)ethyl.
- R 1 is , L is selected from C1-C6 alkylene, preferably ethylene; Z is selected from hydrogen, hydroxyl, C1-C6 alkoxy, R a R b N-, preferably hydrogen, hydroxyl, N,N- Dimethylamino, methoxy.
- R 1 is When L is selected from direct bond, C1-C6 alkylene, preferably from direct bond, methylene, ethylene.
- R 1 is selected from , L is a direct key.
- R 1 is selected from , each L is independently selected from a direct bond, a C1-C6 alkylene group, preferably a direct bond, a methylene group; each Y is independently selected from hydrogen, a C1-C6 alkyl group, preferably a C1-C6 alkyl group , or preferably selected from hydrogen, methyl, or more preferably methyl.
- R 1 is , L is a direct bond;
- Y is selected from hydrogen, C1-C6 alkyl, preferably from C1-C6 alkyl, or preferably from hydrogen, methyl, or more preferably methyl.
- R 1 is selected from , each L is independently selected from C1-C6 alkylene, preferably ethylene.
- R 1 is , L is selected from C1-C6 alkylene, preferably ethylene; Y is selected from hydrogen, C1-C6 alkyl, preferably hydrogen and methyl.
- R 1 is When L is selected from C1-C6 alkylene, preferably ethylene; Y is selected from hydrogen, C1-C6 alkyl, preferably from C1-C6 alkyl, or preferably from hydrogen, methyl, or more preferably is methyl.
- R 1 is When , L is selected from C1-C6 alkylene, preferably ethylene; Z is selected from hydrogen, hydroxyl, R a R b N-, preferably hydrogen, hydroxyl, N,N-dimethylamino.
- R 1 is When , L is selected from C1-C6 alkylene, preferably ethylene; Z is selected from hydrogen, hydroxyl, R a R b N-, preferably hydrogen, hydroxyl, amino, N,N-dimethylamino.
- R 1 is selected from , each L is independently selected from C1-C6 alkylene, preferably ethylene; each Z is independently selected from hydrogen, hydroxyl, R a R b N-, preferably hydrogen, hydroxyl, amino, N,N - Dimethylamino.
- R 1 is When L is selected from C1-C6 alkylene, preferably ethylene; Z is selected from hydroxyl, C1-C6 alkoxy, R a R b N-, preferably selected from hydroxyl, methoxy, N,N- Dimethylamino.
- R a , R b are each independently selected from H, methyl.
- X 1 , X 2 , X 3 , X 4 are each independently selected from C, CH, N, O, S.
- X 1 , X 2 , X 3 , X 4 are each independently selected from C, CH, N, S.
- Y 1 , Y 2 , Y 3 , Y 4 are each independently selected from C, CH, N, O, S.
- Y 1 , Y 2 , Y 3 , Y 4 are each independently selected from C, CH, N.
- R3 is selected from hydrogen, halogen, haloC1-C6 alkyl (eg, trifluoromethyl), C1-C6 alkyl (eg, methyl), C1-C6 alkoxy (eg, , methoxy), C3-C6 cycloalkyl (eg, cyclopropyl).
- R3 is selected from hydrogen, fluoro, chloro, bromo, trifluoromethyl, methyl, methoxy, cyclopropyl.
- R 4 , R 5 are each independently selected from hydrogen, fluorine, chlorine, and R 4 , R 5 are not both hydrogen.
- R 4 is selected from fluoro, chloro, and R 5 is hydrogen.
- the present invention provides a compound of the general formula represented by formula (IV), or a stereoisomer of the compound, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable compound thereof solvates,
- Z 6 and Z 7 are each independently selected from hydrogen, C1-C6 alkyl, halogenated C1-C6 alkyl, C3-C6 cycloalkyl, halogenated C3-C6 cycloalkyl, or, Z 6 , Z 7 and Their commonly connected N atoms together form a substituted or unsubstituted 4-8 membered heterocycle containing 1-2 heteroatoms, and the substituents are selected from halogen, C1-C6 alkyl, C3-C8 cycloalkyl;
- R 1 is selected from and R 1 is not hydrogen
- Each L is independently selected from direct bond, C1-C6 alkylene
- Each Y is independently selected from hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, R a R b N-C1-C6 alkyl, HO-C1-C6 alkyl;
- Each Z is independently selected from hydrogen, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl, C3-C6 cycloalkyl-O-, HO-C1-C6 alkyl, R a R b N-, R a R b N-C1-C6 alkyl;
- R a , R b are each independently selected from hydrogen, C1-C6 alkyl
- X 1 , X 2 , X 3 , and X 4 are each independently selected from C, CH, CH 2 , N, NH, O, S;
- Y 1 , Y 2 , Y 3 , Y 4 are each independently selected from C, CH, CH 2 , N, NH, O, S;
- R is selected from hydrogen, halogen, halogenated C1-C6 alkyl (eg, trifluoromethyl), cyano, nitro, C1-C6 alkyl (eg, methyl, ethyl), C1-C6 alkoxy group (eg, methoxy), C3-C6 cycloalkyl (eg, cyclopropyl), C2-C6 alkenyl (eg, vinyl);
- R 4 and R 5 are each independently selected from hydrogen, fluorine, chlorine, bromine, iodine, C1-C6 alkyl, and R 4 and R 5 are not hydrogen at the same time.
- Z 6 , Z 7 are each independently selected from hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl.
- Z 6 , Z 7 are each independently selected from hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, and Z 6 , Z 7 are not both hydrogen.
- Z 6 , Z 7 are each independently selected from hydrogen, methyl, ethyl, isopropyl, cyclopropyl, and Z 6 , Z 7 are not both hydrogen.
- Z 6 , Z 7 are formed together with the N atom to which they are commonly attached (preferably ).
- Z 6 is hydrogen, methyl;
- Z 7 is selected from methyl, ethyl, isopropyl, cyclopropyl; or, Z 6 , Z 7 are formed together with the N atom to which they are commonly attached
- each L is independently selected from a direct bond, methylene, ethylene.
- each Z is independently selected from hydrogen, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, R a R b N-.
- each Z is independently selected from hydrogen, hydroxy, C1-C6 alkoxy, R a R b N-.
- each Y is independently selected from hydrogen, methyl, ethyl, isopropyl, cyclopropyl, 2-hydroxyethyl, 2-(N,N-dimethylamino)ethyl.
- each Z is independently selected from hydrogen, hydroxy, amino, N,N-dimethylamino, methoxy.
- R 1 is When L is selected from direct bond, C1-C6 alkylene, preferably from direct bond, methylene, ethylene; Y is selected from hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, HO-C1 -C6 alkyl, R a R b N-C1-C6 alkyl, preferably selected from hydrogen, methyl, ethyl, isopropyl, cyclopropyl, 2-hydroxyethyl, 2-(N,N-di methylamino)ethyl.
- R 1 is , L is selected from C1-C6 alkylene, preferably ethylene; Z is selected from hydrogen, hydroxyl, C1-C6 alkoxy, R a R b N-, preferably hydrogen, hydroxyl, N,N- Dimethylamino, methoxy.
- R 1 is When L is selected from direct bond, C1-C6 alkylene, preferably from direct bond, methylene, ethylene.
- R 1 is selected from , L is a direct key.
- R 1 is selected from , each L is independently selected from a direct bond, a C1-C6 alkylene group, preferably a direct bond, a methylene group; each Y is independently selected from hydrogen, a C1-C6 alkyl group, preferably a C1-C6 alkyl group , or preferably selected from hydrogen, methyl, or more preferably methyl.
- R 1 is , L is a direct bond;
- Y is selected from hydrogen, C1-C6 alkyl, preferably from C1-C6 alkyl, or preferably from hydrogen, methyl, or more preferably methyl.
- R 1 is selected from , each L is independently selected from C1-C6 alkylene, preferably ethylene.
- R 1 is , L is selected from C1-C6 alkylene, preferably ethylene; Y is selected from hydrogen, C1-C6 alkyl, preferably hydrogen and methyl.
- R 1 is When L is selected from C1-C6 alkylene, preferably ethylene; Y is selected from hydrogen, C1-C6 alkyl, preferably from C1-C6 alkyl, or preferably from hydrogen, methyl, or more preferably is methyl.
- R 1 is When , L is selected from C1-C6 alkylene, preferably ethylene; Z is selected from hydrogen, hydroxyl, R a R b N-, preferably hydrogen, hydroxyl, N,N-dimethylamino.
- R 1 is When , L is selected from C1-C6 alkylene, preferably ethylene; Z is selected from hydrogen, hydroxyl, R a R b N-, preferably hydrogen, hydroxyl, amino, N,N-dimethylamino.
- R 1 is selected from , each L is independently selected from C1-C6 alkylene, preferably ethylene; each Z is independently selected from hydrogen, hydroxyl, R a R b N-, preferably hydrogen, hydroxyl, amino, N,N - Dimethylamino.
- R 1 is When L is selected from C1-C6 alkylene, preferably ethylene; Z is selected from hydroxyl, C1-C6 alkoxy, R a R b N-, preferably selected from hydroxyl, methoxy, N,N- Dimethylamino.
- R a , R b are each independently selected from H, methyl.
- X 1 , X 2 , X 3 , X 4 are each independently selected from C, CH, N, O, S.
- X 1 , X 2 , X 3 , X 4 are each independently selected from C, CH, N, S.
- Y 1 , Y 2 , Y 3 , Y 4 are each independently selected from C, CH, N, O, S.
- Y 1 , Y 2 , Y 3 , Y 4 are each independently selected from C, CH, N.
- R3 is selected from hydrogen, halogen, haloC1-C6 alkyl (eg, trifluoromethyl), C1-C6 alkyl (eg, methyl), C1-C6 alkoxy (eg, , methoxy), C3-C6 cycloalkyl (eg, cyclopropyl).
- R3 is selected from hydrogen, fluoro, chloro, bromo, trifluoromethyl, methyl, methoxy, cyclopropyl.
- R 4 , R 5 are each independently selected from hydrogen, fluorine, chlorine, and R 4 , R 5 are not both hydrogen.
- R 4 is selected from fluoro, chloro, and R 5 is hydrogen.
- the present invention provides compounds of the following general formula:
- R 1 is selected from and R 1 is not hydrogen
- Each L is independently selected from direct bond, C1-C6 alkylene
- Each Y is independently selected from hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, R a R b N-C1-C6 alkyl, HO-C1-C6 alkyl;
- Each Z is independently selected from hydrogen, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl, C3-C6 cycloalkyl-O-, HO-C1-C6 alkyl, R a R b N-, R a R b N-C1-C6 alkyl;
- R a , R b are each independently selected from hydrogen, C1-C6 alkyl
- X 1 , X 2 , X 3 , and X 4 are each independently selected from C, CH, CH 2 , N, NH, O, S;
- R 2 is selected from:
- Z 1 and Z 2 are each independently selected from C1-C6 alkyl, C3-C8 cycloalkyl;
- Z 3 and Z 4 are each independently selected from hydrogen, C1-C6 alkyl, halogenated C1-C6 alkyl, C3-C6 cycloalkyl, halogenated C3-C6 cycloalkyl, and Z 4 is not hydrogen ;
- Z 5 is selected from C1-C6 alkyl, halogenated C1-C6 alkyl, C3-C8 cycloalkyl, C1-C6 heteroatom-containing alkyl, C3-C8 heteroatom-containing cycloalkyl;
- Z 6 and Z 7 are each independently selected from hydrogen, C1-C6 alkyl, halogenated C1-C6 alkyl, C3-C6 cycloalkyl, halogenated C3-C6 cycloalkyl, or Z 6 , Z 7 together with the N atoms to which they are commonly attached to form a substituted or unsubstituted 4-8 membered heterocycle containing 1 to 2 heteroatoms, the substituents being selected from halogen, C1-C6 alkyl, C3-C8 cycloalkyl ;
- R is selected from hydrogen, halogen, halogenated C1-C6 alkyl (eg, trifluoromethyl), cyano, nitro, C1-C6 alkyl (eg, methyl, ethyl), C1-C6 alkoxy (eg, methoxy), C3-C6 cycloalkyl (eg, cyclopropyl), C2-C6 alkenyl (eg, vinyl).
- C1-C6 alkyl eg, methyl, ethyl
- C1-C6 alkoxy eg, methoxy
- C3-C6 cycloalkyl eg, cyclopropyl
- C2-C6 alkenyl eg, vinyl
- each L is independently selected from a direct bond, methylene, ethylene.
- each Z is independently selected from hydrogen, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, R a R b N-.
- each Z is independently selected from hydrogen, hydroxy, C1-C6 alkoxy, R a R b N-.
- each Y is independently selected from hydrogen, methyl, ethyl, isopropyl, cyclopropyl, 2-hydroxyethyl, 2-(N,N-dimethylamino)ethyl.
- each Z is independently selected from hydrogen, hydroxy, amino, N,N-dimethylamino, methoxy.
- R a , R b are each independently selected from H, methyl.
- X 1 , X 2 , X 3 , X 4 are each independently selected from C, CH, N, O, S.
- X 1 , X 2 , X 3 , X 4 are each independently selected from C, CH, N, S.
- Z 1 , Z 2 are each independently selected from C1-C6 alkyl.
- Z 1 , Z 2 are methyl groups.
- Z 3 , Z 4 are each independently selected from hydrogen, C1-C6 alkyl, haloC1-C6 alkyl, C3-C6 cycloalkyl, and Z 4 is not hydrogen.
- Z3, Z4 are each independently selected from hydrogen, methyl, ethyl, isopropyl, cyclopropyl, -CF3 , and Z4 is not hydrogen.
- Z 3 is selected from hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl.
- Z 4 is selected from C1-C6 alkyl, halogenated C1-C6 alkyl, C3-C6 cycloalkyl.
- Z3 is selected from hydrogen, methyl, ethyl, cyclopropyl.
- Z4 is selected from methyl, ethyl, isopropyl, -CF3 , cyclopropyl.
- Z 5 is selected from C1-C6 alkyl.
- Z5 is selected from methyl, ethyl, isopropyl.
- Z 6 , Z 7 are each independently selected from hydrogen, C1-C6 alkyl.
- Z 6 , Z 7 are each independently selected from hydrogen, C1-C6 alkyl, and Z 6 , Z 7 are not both hydrogen.
- Z 6 , Z 7 are each independently selected from hydrogen, methyl, ethyl, isopropyl, and Z 6 , Z 7 are not both hydrogen.
- Z 6 , Z 7 are formed together with the N atom to which they are commonly attached (preferably ).
- Z6 is hydrogen, methyl; Z7 is selected from methyl, ethyl, isopropyl; or, Z6 , Z7 are formed together with the N atom to which they are commonly attached
- R3 is selected from hydrogen, fluorine, chlorine, bromine, trifluoromethyl, cyano, nitro, methyl, ethyl, methoxy, cyclopropyl, vinyl.
- the present invention provides a compound of the general formula represented by formula (I'), or a stereoisomer of the compound, a prodrug thereof, a pharmaceutically acceptable salt thereof or a pharmaceutically acceptable salt thereof. accepted solvates,
- Z 1 and Z 2 are each independently selected from C1-C6 alkyl, C3-C8 cycloalkyl;
- R 1 is selected from and R 1 is not hydrogen
- Each L is independently selected from direct bond, C1-C6 alkylene
- Each Y is independently selected from hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, R a R b N-C1-C6 alkyl, HO-C1-C6 alkyl;
- Each Z is independently selected from hydrogen, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl, C3-C6 cycloalkyl-O-, HO-C1-C6 alkyl, R a R b N-, R a R b N-C1-C6 alkyl;
- R a , R b are each independently selected from hydrogen, C1-C6 alkyl
- X 1 , X 2 , X 3 , and X 4 are each independently selected from C, CH, CH 2 , N, NH, O, S;
- R is selected from hydrogen, halogen, halogenated C1-C6 alkyl (eg, trifluoromethyl), cyano, nitro, C1-C6 alkyl (eg, methyl, ethyl), C1-C6 alkoxy (eg, methoxy), C3-C6 cycloalkyl (eg, cyclopropyl), C2-C6 alkenyl (eg, vinyl).
- C1-C6 alkyl eg, methyl, ethyl
- C1-C6 alkoxy eg, methoxy
- C3-C6 cycloalkyl eg, cyclopropyl
- C2-C6 alkenyl eg, vinyl
- Z 1 , Z 2 are each independently selected from C1-C6 alkyl.
- Z 1 , Z 2 are methyl groups.
- each L is independently selected from a direct bond, methylene, ethylene.
- each Z is independently selected from hydrogen, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, R a R b N-.
- each Z is independently selected from hydrogen, hydroxy, C1-C6 alkoxy, R a R b N-.
- each Y is independently selected from hydrogen, methyl, ethyl, isopropyl, cyclopropyl, 2-hydroxyethyl, 2-(N,N-dimethylamino)ethyl.
- each Z is independently selected from hydrogen, hydroxy, amino, N,N-dimethylamino, methoxy.
- R 1 is When L is selected from direct bond, C1-C6 alkylene, preferably from direct bond, methylene, ethylene; Y is selected from hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, HO-C1 -C6 alkyl, R a R b N-C1-C6 alkyl, preferably selected from hydrogen, methyl, ethyl, isopropyl, cyclopropyl, 2-hydroxyethyl, 2-(N,N-di methylamino)ethyl.
- R 1 is , L is selected from C1-C6 alkylene, preferably ethylene; Z is selected from hydrogen, hydroxyl, C1-C6 alkoxy, R a R b N-, preferably hydrogen, hydroxyl, N,N- Dimethylamino, methoxy.
- R 1 is When L is selected from direct bond, C1-C6 alkylene, preferably from direct bond, methylene, ethylene.
- R 1 is selected from , L is a direct key.
- R 1 is When L is selected from direct bond, C1-C6 alkylene, preferably selected from direct bond, methylene; Y is selected from hydrogen, C1-C6 alkyl, preferably selected from C1-C6 alkyl, or preferably selected from hydrogen , methyl, or more preferably methyl.
- R 1 is , L is selected from direct bond, C1-C6 alkylene, preferably direct bond, methylene; Y is selected from hydrogen, C1-C6 alkyl, preferably hydrogen, methyl.
- R 1 is , L is a direct bond; Y is selected from hydrogen and C1-C6 alkyl, preferably from hydrogen and methyl.
- R 1 is selected from , each L is independently selected from C1-C6 alkylene, preferably ethylene.
- R 1 is , L is selected from C1-C6 alkylene, preferably ethylene; Y is selected from hydrogen, C1-C6 alkyl, preferably hydrogen and methyl.
- R 1 is When L is selected from C1-C6 alkylene, preferably ethylene; Y is selected from hydrogen, C1-C6 alkyl, preferably from C1-C6 alkyl, or preferably from hydrogen, methyl, or more preferably is methyl.
- R 1 is When , L is selected from C1-C6 alkylene, preferably ethylene; Z is selected from hydrogen, hydroxyl, R a R b N-, preferably hydrogen, hydroxyl, N,N-dimethylamino.
- R 1 is When , L is selected from C1-C6 alkylene, preferably ethylene; Z is selected from hydrogen, hydroxyl, R a R b N-, preferably hydrogen, hydroxyl, amino, N,N-dimethylamino.
- R 1 is When L is selected from C1-C6 alkylene, preferably ethylene; Z is selected from hydroxyl, C1-C6 alkoxy, R a R b N-, preferably selected from hydroxyl, methoxy, N,N- Dimethylamino.
- R a , R b are each independently selected from H, methyl.
- X 1 , X 2 , X 3 , X 4 are each independently selected from C, CH, N, O, S.
- X 1 , X 2 , X 3 , X 4 are each independently selected from C, CH, N, S.
- R3 is selected from hydrogen, halogen, C1-C6 alkyl (eg, methyl, ethyl), C3-C6 cycloalkyl (eg, cyclopropyl), C2-C6 alkenyl (eg, , vinyl).
- R3 is selected from hydrogen, fluoro, chloro, bromo, methyl, ethyl, cyclopropyl, vinyl.
- the present invention provides a compound of general formula (II'), or a stereoisomer of the compound, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof. accepted solvates,
- Z 3 and Z 4 are each independently selected from hydrogen, C1-C6 alkyl, halogenated C1-C6 alkyl, C3-C6 cycloalkyl, halogenated C3-C6 cycloalkyl, and Z 4 is not hydrogen;
- R 1 is selected from and R 1 is not hydrogen
- Each L is independently selected from direct bond, C1-C6 alkylene
- Each Y is independently selected from hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, R a R b N-C1-C6 alkyl, HO-C1-C6 alkyl;
- Each Z is independently selected from hydrogen, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl, C3-C6 cycloalkyl-O-, HO-C1-C6 alkyl, R a R b N-, R a R b N-C1-C6 alkyl;
- R a , R b are each independently selected from hydrogen, C1-C6 alkyl
- X 1 , X 2 , X 3 , and X 4 are each independently selected from C, CH, CH 2 , N, NH, O, S;
- R is selected from hydrogen, halogen, halogenated C1-C6 alkyl (eg, trifluoromethyl), cyano, nitro, C1-C6 alkyl (eg, methyl, ethyl), C1-C6 alkoxy (eg, methoxy), C3-C6 cycloalkyl (eg, cyclopropyl), C2-C6 alkenyl (eg, vinyl).
- C1-C6 alkyl eg, methyl, ethyl
- C1-C6 alkoxy eg, methoxy
- C3-C6 cycloalkyl eg, cyclopropyl
- C2-C6 alkenyl eg, vinyl
- Z 3 , Z 4 are each independently selected from hydrogen, C1-C6 alkyl, haloC1-C6 alkyl, C3-C6 cycloalkyl, and Z 4 is not hydrogen.
- Z3, Z4 are each independently selected from hydrogen, methyl, ethyl, isopropyl, cyclopropyl, -CF3 , and Z4 is not hydrogen.
- Z 3 is selected from hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl.
- Z 4 is selected from C1-C6 alkyl, halogenated C1-C6 alkyl, C3-C6 cycloalkyl.
- Z3 is selected from hydrogen, methyl, ethyl, cyclopropyl.
- Z4 is selected from methyl, ethyl, isopropyl, -CF3 , cyclopropyl.
- R 1 is selected from and R 1 is not hydrogen.
- each L is independently selected from a direct bond, methylene, ethylene.
- each Z is independently selected from hydrogen, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, R a R b N-.
- each Z is independently selected from hydrogen, hydroxy, C1-C6 alkoxy, R a R b N-.
- each Y is independently selected from hydrogen, methyl, ethyl, isopropyl, cyclopropyl, 2-hydroxyethyl, 2-(N,N-dimethylamino)ethyl.
- each Z is independently selected from hydrogen, hydroxy, amino, N,N-dimethylamino, methoxy.
- R 1 is When L is selected from direct bond, C1-C6 alkylene, preferably from direct bond, methylene, ethylene; Y is selected from hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, HO-C1 -C6 alkyl, R a R b N-C1-C6 alkyl, preferably selected from hydrogen, methyl, ethyl, isopropyl, cyclopropyl, 2-hydroxyethyl, 2-(N,N-di methylamino)ethyl.
- R 1 is , L is selected from C1-C6 alkylene, preferably ethylene; Z is selected from hydrogen, hydroxyl, C1-C6 alkoxy, R a R b N-, preferably hydrogen, hydroxyl, N,N- Dimethylamino, methoxy.
- R 1 is When L is selected from direct bond, C1-C6 alkylene, preferably from direct bond, methylene, ethylene.
- R 1 is selected from , L is a direct key.
- R 1 is selected from , each L is independently selected from a direct bond, a C1-C6 alkylene group, preferably a direct bond, a methylene group; each Y is independently selected from hydrogen, a C1-C6 alkyl group, preferably a C1-C6 alkyl group , or preferably selected from hydrogen, methyl, or more preferably methyl.
- R 1 is , L is a direct bond; Y is selected from hydrogen and C1-C6 alkyl, preferably from hydrogen and methyl.
- R 1 is When L is selected from C1-C6 alkylene, preferably ethylene.
- R 1 is , L is selected from C1-C6 alkylene, preferably ethylene; Y is selected from hydrogen, C1-C6 alkyl, preferably hydrogen and methyl.
- R 1 is When L is selected from C1-C6 alkylene, preferably ethylene; Y is selected from hydrogen, C1-C6 alkyl, preferably from C1-C6 alkyl, or preferably from hydrogen, methyl, or more preferably is methyl.
- R 1 is When , L is selected from C1-C6 alkylene, preferably ethylene; Z is selected from hydrogen, hydroxyl, R a R b N-, preferably hydrogen, hydroxyl, N,N-dimethylamino.
- R 1 is When , L is selected from C1-C6 alkylene, preferably ethylene; Z is selected from hydrogen, hydroxyl, R a R b N-, preferably hydrogen, hydroxyl, amino, N,N-dimethylamino.
- R 1 is selected from , each L is independently selected from C1-C6 alkylene, preferably ethylene; each Z is independently selected from hydrogen, hydroxyl, R a R b N-, preferably hydrogen, hydroxyl, amino, N,N - Dimethylamino.
- R 1 is When L is selected from C1-C6 alkylene, preferably ethylene; Z is selected from hydroxyl, C1-C6 alkoxy, R a R b N-, preferably selected from hydroxyl, methoxy, N,N- Dimethylamino.
- R a , R b are each independently selected from H, methyl.
- X 1 , X 2 , X 3 , X 4 are each independently selected from C, CH, N, O, S.
- X 1 , X 2 , X 3 , X 4 are each independently selected from C, CH, N, S.
- R 3 is selected from hydrogen, halogen, halogenated C1-C6 alkyl (eg, trifluoromethyl), cyano, nitro, C1-C6 alkyl (eg, methyl), C1- C6 alkoxy (eg, methoxy), C3-C6 cycloalkyl (eg, cyclopropyl).
- R3 is selected from hydrogen, fluoro, chloro, bromo, trifluoromethyl, cyano, nitro, methyl, methoxy, cyclopropyl.
- the present invention provides a compound of the general formula represented by formula (III'), or a stereoisomer of the compound, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof. accepted solvates,
- Z 5 is selected from C1-C6 alkyl, halogenated C1-C6 alkyl, C3-C8 cycloalkyl, C1-C6 heteroatom-containing alkyl, C3-C8 heteroatom-containing cycloalkyl;
- R 1 is selected from and R 1 is not hydrogen
- Each L is independently selected from direct bond, C1-C6 alkylene
- Each Y is independently selected from hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, R a R b N-C1-C6 alkyl, HO-C1-C6 alkyl;
- Each Z is independently selected from hydrogen, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl, C3-C6 cycloalkyl-O-, HO-C1-C6 alkyl, R a R b N-, R a R b N-C1-C6 alkyl;
- R a , R b are each independently selected from hydrogen, C1-C6 alkyl
- X 1 , X 2 , X 3 , and X 4 are each independently selected from C, CH, CH 2 , N, NH, O, S;
- R is selected from hydrogen, halogen, halogenated C1-C6 alkyl (eg, trifluoromethyl), cyano, nitro, C1-C6 alkyl (eg, methyl, ethyl), C1-C6 alkoxy (eg, methoxy), C3-C6 cycloalkyl (eg, cyclopropyl), C2-C6 alkenyl (eg, vinyl).
- C1-C6 alkyl eg, methyl, ethyl
- C1-C6 alkoxy eg, methoxy
- C3-C6 cycloalkyl eg, cyclopropyl
- C2-C6 alkenyl eg, vinyl
- Z 5 is selected from C1-C6 alkyl.
- Z5 is selected from methyl, ethyl, isopropyl.
- each L is independently selected from a direct bond, methylene, ethylene.
- each Z is independently selected from hydrogen, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, R a R b N-.
- each Z is independently selected from hydrogen, hydroxy, C1-C6 alkoxy, R a R b N-.
- each Y is independently selected from hydrogen, methyl, ethyl, isopropyl, cyclopropyl, 2-hydroxyethyl, 2-(N,N-dimethylamino)ethyl.
- each Z is independently selected from hydrogen, hydroxy, amino, N,N-dimethylamino, methoxy.
- R 1 is When L is selected from direct bond, C1-C6 alkylene, preferably from direct bond, methylene, ethylene; Y is selected from hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, HO-C1 -C6 alkyl, R a R b N-C1-C6 alkyl, preferably selected from hydrogen, methyl, ethyl, isopropyl, cyclopropyl, 2-hydroxyethyl, 2-(N,N-di methylamino)ethyl.
- R 1 is , L is selected from C1-C6 alkylene, preferably ethylene; Z is selected from hydrogen, hydroxyl, C1-C6 alkoxy, R a R b N-, preferably hydrogen, hydroxyl, N,N- Dimethylamino, methoxy.
- R 1 is When L is selected from direct bond, C1-C6 alkylene, preferably from direct bond, methylene, ethylene.
- R 1 is selected from , L is a direct key.
- R 1 is selected from , each L is independently selected from a direct bond, a C1-C6 alkylene group, preferably a direct bond, a methylene group; each Y is independently selected from hydrogen, a C1-C6 alkyl group, preferably a C1-C6 alkyl group , or preferably selected from hydrogen, methyl, or more preferably methyl.
- R 1 is , L is a direct bond;
- Y is selected from hydrogen, C1-C6 alkyl, preferably from C1-C6 alkyl, or preferably from hydrogen, methyl, or more preferably methyl.
- R 1 is selected from , each L is independently selected from C1-C6 alkylene, preferably ethylene.
- R 1 is , L is selected from C1-C6 alkylene, preferably ethylene; Y is selected from hydrogen, C1-C6 alkyl, preferably hydrogen and methyl.
- R 1 is When L is selected from C1-C6 alkylene, preferably ethylene; Y is selected from hydrogen, C1-C6 alkyl, preferably from C1-C6 alkyl, or preferably from hydrogen, methyl, or more preferably is methyl.
- R 1 is When , L is selected from C1-C6 alkylene, preferably ethylene; Z is selected from hydrogen, hydroxyl, R a R b N-, preferably hydrogen, hydroxyl, N,N-dimethylamino.
- R 1 is When , L is selected from C1-C6 alkylene, preferably ethylene; Z is selected from hydrogen, hydroxyl, R a R b N-, preferably hydrogen, hydroxyl, amino, N,N-dimethylamino.
- R 1 is selected from , each L is independently selected from C1-C6 alkylene, preferably ethylene; each Z is independently selected from hydrogen, hydroxyl, R a R b N-, preferably hydrogen, hydroxyl, amino, N,N - Dimethylamino.
- R 1 is When L is selected from C1-C6 alkylene, preferably ethylene; Z is selected from hydroxyl, C1-C6 alkoxy, R a R b N-, preferably selected from hydroxyl, methoxy, N,N- Dimethylamino.
- R a , R b are each independently selected from H, methyl.
- X 1 , X 2 , X 3 , X 4 are each independently selected from C, CH, N, O, S.
- X 1 , X 2 , X 3 , X 4 are each independently selected from C, CH, N, S.
- R3 is selected from hydrogen, halogen, haloC1-C6 alkyl (eg, trifluoromethyl), C1-C6 alkyl (eg, methyl), C1-C6 alkoxy (eg, , methoxy), C3-C6 cycloalkyl (eg, cyclopropyl).
- R3 is selected from hydrogen, fluoro, chloro, bromo, trifluoromethyl, methyl, methoxy, cyclopropyl.
- the present invention provides a compound of the general formula represented by formula (IV'), or a stereoisomer of the compound, a prodrug thereof, a pharmaceutically acceptable salt thereof, or a pharmaceutically acceptable salt thereof. accepted solvates,
- Z 6 and Z 7 are each independently selected from hydrogen, C1-C6 alkyl, halogenated C1-C6 alkyl, C3-C6 cycloalkyl, halogenated C3-C6 cycloalkyl, or, Z 6 , Z 7 and Their commonly connected N atoms together form a substituted or unsubstituted 4-8 membered heterocycle containing 1-2 heteroatoms, and the substituents are selected from halogen, C1-C6 alkyl, C3-C8 cycloalkyl;
- R 1 is selected from and R 1 is not hydrogen
- Each L is independently selected from direct bond, C1-C6 alkylene
- Each Y is independently selected from hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, R a R b N-C1-C6 alkyl, HO-C1-C6 alkyl;
- Each Z is independently selected from hydrogen, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, C3-C6 cycloalkyl, C3-C6 cycloalkyl-O-, HO-C1-C6 alkyl, R a R b N-, R a R b N-C1-C6 alkyl;
- R a , R b are each independently selected from hydrogen, C1-C6 alkyl
- X 1 , X 2 , X 3 , and X 4 are each independently selected from C, CH, CH 2 , N, NH, O, S;
- R is selected from hydrogen, halogen, halogenated C1-C6 alkyl (eg, trifluoromethyl), cyano, nitro, C1-C6 alkyl (eg, methyl, ethyl), C1-C6 alkoxy (eg, methoxy), C3-C6 cycloalkyl (eg, cyclopropyl), C2-C6 alkenyl (eg, vinyl).
- C1-C6 alkyl eg, methyl, ethyl
- C1-C6 alkoxy eg, methoxy
- C3-C6 cycloalkyl eg, cyclopropyl
- C2-C6 alkenyl eg, vinyl
- Z 6 , Z 7 are each independently selected from hydrogen, C1-C6 alkyl.
- Z 6 , Z 7 are each independently selected from hydrogen, C1-C6 alkyl, and Z 6 , Z 7 are not both hydrogen.
- Z 6 , Z 7 are each independently selected from hydrogen, methyl, ethyl, isopropyl, and Z 6 , Z 7 are not both hydrogen.
- Z 6 , Z 7 are formed together with the N atom to which they are commonly attached (preferably ).
- Z6 is hydrogen, methyl; Z7 is selected from methyl, ethyl, isopropyl; or, Z6 , Z7 are formed together with the N atom to which they are commonly attached
- each L is independently selected from a direct bond, methylene, ethylene.
- each Z is independently selected from hydrogen, hydroxy, C1-C6 alkyl, C1-C6 alkoxy, R a R b N-.
- each Z is independently selected from hydrogen, hydroxy, C1-C6 alkoxy, R a R b N-.
- each Y is independently selected from hydrogen, methyl, ethyl, isopropyl, cyclopropyl, 2-hydroxyethyl, 2-(N,N-dimethylamino)ethyl.
- each Z is independently selected from hydrogen, hydroxy, amino, N,N-dimethylamino, methoxy.
- R 1 is When L is selected from direct bond, C1-C6 alkylene, preferably from direct bond, methylene, ethylene; Y is selected from hydrogen, C1-C6 alkyl, C3-C6 cycloalkyl, HO-C1 -C6 alkyl, R a R b N-C1-C6 alkyl, preferably selected from hydrogen, methyl, ethyl, isopropyl, cyclopropyl, 2-hydroxyethyl, 2-(N,N-di methylamino)ethyl.
- R 1 is , L is selected from C1-C6 alkylene, preferably ethylene; Z is selected from hydrogen, hydroxyl, C1-C6 alkoxy, R a R b N-, preferably hydrogen, hydroxyl, N,N- Dimethylamino, methoxy.
- R 1 is When L is selected from direct bond, C1-C6 alkylene, preferably from direct bond, methylene, ethylene.
- R 1 is selected from , L is a direct key.
- R 1 is selected from , each L is independently selected from a direct bond, a C1-C6 alkylene group, preferably a direct bond, a methylene group; each Y is independently selected from hydrogen, a C1-C6 alkyl group, preferably a C1-C6 alkyl group , or preferably selected from hydrogen, methyl, or more preferably methyl.
- R 1 is , L is a direct bond;
- Y is selected from hydrogen, C1-C6 alkyl, preferably from C1-C6 alkyl, or preferably from hydrogen, methyl, or more preferably methyl.
- R 1 is selected from , each L is independently selected from C1-C6 alkylene, preferably ethylene.
- R 1 is , L is selected from C1-C6 alkylene, preferably ethylene; Y is selected from hydrogen, C1-C6 alkyl, preferably hydrogen and methyl.
- R 1 is When L is selected from C1-C6 alkylene, preferably ethylene; Y is selected from hydrogen, C1-C6 alkyl, preferably from C1-C6 alkyl, or preferably from hydrogen, methyl, or more preferably is methyl.
- R 1 is When , L is selected from C1-C6 alkylene, preferably ethylene; Z is selected from hydrogen, hydroxyl, R a R b N-, preferably hydrogen, hydroxyl, N,N-dimethylamino.
- R 1 is When , L is selected from C1-C6 alkylene, preferably ethylene; Z is selected from hydrogen, hydroxyl, R a R b N-, preferably hydrogen, hydroxyl, amino, N,N-dimethylamino.
- R 1 is selected from , each L is independently selected from C1-C6 alkylene, preferably ethylene; each Z is independently selected from hydrogen, hydroxyl, R a R b N-, preferably hydrogen, hydroxyl, amino, N,N - Dimethylamino.
- R 1 is When L is selected from C1-C6 alkylene, preferably ethylene; Z is selected from hydroxyl, C1-C6 alkoxy, R a R b N-, preferably selected from hydroxyl, methoxy, N,N- Dimethylamino.
- R a , R b are each independently selected from H, methyl.
- X 1 , X 2 , X 3 , X 4 are each independently selected from C, CH, N, O, S.
- X 1 , X 2 , X 3 , X 4 are each independently selected from C, CH, N, S.
- R3 is selected from hydrogen, halogen, haloC1-C6 alkyl (eg, trifluoromethyl), C1-C6 alkyl (eg, methyl), C1-C6 alkoxy (eg, , methoxy), C3-C6 cycloalkyl (eg, cyclopropyl).
- R3 is selected from hydrogen, fluoro, chloro, bromo, trifluoromethyl, methyl, methoxy, cyclopropyl.
- the present invention provides compounds of the following general formula:
- R1 is selected from :
- L is selected from a direct bond, methylene or
- Y is selected from hydrogen, methyl, ethyl, propyl, isopropyl, cyclopropyl, 2-(N,N-dimethylamino)ethyl, 2-(N,N-diethylamino)ethyl base, 2-(N,N-dipropylamino)ethyl, 2-(N,N-diisopropylamino)ethyl, 2-hydroxyethyl, 2-methoxyethyl, 2-ethyl oxyethyl, 2-propoxyethyl, 2-isopropoxyethyl, 2-cyclopropoxyethyl;
- Z is selected from hydrogen, hydroxyl, methoxy, ethoxy, propoxy, isopropoxy, amino, N,N-dimethylamino, N,N-diethylamino, N,N- Dipropylamino, N,N-diisopropylamino;
- X 1 , X 2 , X 3 , X 4 each independently selected from C, N, O, S;
- R 2 is selected from:
- Z 1 and Z 2 are each independently selected from C1-C6 alkyl, C3-C8 cycloalkyl;
- Z 3 and Z 4 are each independently selected from hydrogen, C1-C6 alkyl, C1-C6 fluorine-containing alkyl, C3-C6 cycloalkyl, C3-C6 fluorine-containing cycloalkyl, and Z 4 is not hydrogen ;
- Z 5 is selected from C1-C6 alkyl, C1-C6 fluorine-containing alkyl, C3-C8 cycloalkyl, C1-C6 heteroatom-containing alkyl, C3-C8 heteroatom-containing cycloalkyl;
- Z 6 and Z 7 are each independently selected from hydrogen, C1-C6 alkyl, C1-C6 fluorine-containing alkyl, C3-C6 cycloalkyl, C3-C6 fluorine-containing cycloalkyl, or Z 6 , Z 7 together with N forms a substituted or unsubstituted 4-8 membered ring containing 1-2 heteroatoms, and the substituent is selected from halogen, C1-C6 alkyl, C3-C8 cycloalkyl;
- R3 is selected from:
- C1-C6 fluoroalkyl eg, trifluoromethyl
- the present invention also provides a method for preparing the compound described in any of the above-mentioned technical solutions, comprising the following steps:
- the metal palladium catalyst is selected from palladium acetate, tetrakis(triphenylphosphine) palladium, bistriphenylphosphonium palladium dichloride, [1,1'-bis(diphenylphosphine)ferrocene]dichloride palladium , tris(dibenzylideneacetone)dipalladium;
- the alkaline conditions refer to the conditions in which any of the following substances exist: triethylamine, diisopropylethylamine, pyridine, sodium bicarbonate, sodium carbonate, potassium carbonate, cesium carbonate, lithium hydroxide, sodium hydroxide, hydroxide Potassium, sodium hydride, potassium hydride;
- Described acidic condition refers to the condition that any of the following substances exist: acetic acid, trifluoroacetic acid, hydrochloric acid, methanesulfonic acid, p-toluenesulfonic acid, camphorsulfonic acid;
- the present invention also provides a method for preparing the compound described in any of the above-mentioned technical solutions, comprising the following steps:
- the metal palladium catalyst is selected from palladium acetate, tetrakis(triphenylphosphine) palladium, bistriphenylphosphonium palladium dichloride, [1,1'-bis(diphenylphosphine)ferrocene]dichloride palladium , tris(dibenzylideneacetone)dipalladium;
- the alkaline conditions refer to the conditions in which any of the following substances exist: triethylamine, diisopropylethylamine, pyridine, sodium bicarbonate, sodium carbonate, potassium carbonate, cesium carbonate, lithium hydroxide, sodium hydroxide, hydroxide Potassium, sodium hydride, potassium hydride;
- Described acidic condition refers to the condition that any of the following substances exist: acetic acid, trifluoroacetic acid, hydrochloric acid, methanesulfonic acid, p-toluenesulfonic acid, camphorsulfonic acid;
- the present invention provides a pharmaceutical composition
- a pharmaceutical composition comprising the compound described in any of the above technical solutions, its stereoisomer, its prodrug, or its pharmaceutically acceptable salt or pharmaceutically acceptable solvate substance, and optional pharmaceutically acceptable carrier, diluent or excipient.
- the pharmaceutical composition further comprises other tumor immunotherapy drugs.
- the other tumor immunotherapy drugs are selected from PD-1 mAb, PD-L1 mAb, CTLA-4 mAb, TIM-3 mAb, TGF ⁇ mAb, LAG3 antagonist, TLR4 agonist , TLR7 agonists, TLR8 agonists, TLR9 agonists, STING agonists, CAR-T cells, or any combination thereof.
- Methods of preparing various pharmaceutical compositions containing amounts of active ingredients are known, or will be apparent to those skilled in the art in light of the present disclosure. Methods of preparing such pharmaceutical compositions include incorporating suitable pharmaceutical excipients, carriers, diluents, and the like, as described in REMINGTON'S PHARMACEUTICAL SCIENCES, Martin, E.W., ed., Mack Publishing Company, 19th ed. (1995).
- the pharmaceutical formulations of the present invention are manufactured by known methods, including conventional mixing, dissolving or lyophilization methods.
- the compounds of the present invention can be formulated into pharmaceutical compositions and administered to a patient by various routes suitable for the chosen mode of administration, eg, orally or parenterally (by intravenous, intramuscular, topical or subcutaneous routes).
- the compounds of the present invention can be administered systemically, eg, orally, in combination with a pharmaceutically acceptable carrier such as an inert diluent or an assimilable edible carrier. They can be enclosed in hard or soft shell gelatin capsules and can be compressed into tablets.
- a pharmaceutically acceptable carrier such as an inert diluent or an assimilable edible carrier.
- the active compound may be incorporated with one or more excipients and presented in the form of swallowable tablets, buccal tablets, lozenges, capsules, elixirs, suspensions, syrups, wafers, and the like use.
- Such compositions and preparations should contain at least 0.1% active compound.
- the proportions of such compositions and formulations may, of course, vary and may range from about 1% to about 99% by weight of a given unit dosage form.
- the active compound is in an amount such that an effective dosage level can be obtained.
- Tablets, troches, pills, capsules, etc. may also contain: a binder, such as tragacanth, acacia, cornstarch, or gelatin; an excipient, such as dicalcium hydrogen phosphate; a disintegrant, such as cornstarch, Potato starch, alginic acid, etc.; lubricants, such as magnesium stearate; and sweeteners, such as sucrose, fructose, lactose, or aspartame; or flavoring agents, such as peppermint, oil of wintergreen, or cherry flavor.
- a binder such as tragacanth, acacia, cornstarch, or gelatin
- an excipient such as dicalcium hydrogen phosphate
- a disintegrant such as cornstarch, Potato starch, alginic acid, etc.
- lubricants such as magnesium stearate
- sweeteners such as sucrose, fructose, lactose, or aspartame
- flavoring agents such as pepper
- any materials may be present, as coatings, or to otherwise alter the physical form of the solid unit dosage form.
- tablets, pills or capsules may be coated with gelatin, wax, shellac or sugar and the like.
- a syrup or elixir may contain the active compound, sucrose or fructose as a sweetening agent, methyl or propylparaben as a preservative, a dye and a flavoring (such as cherry or orange flavor).
- any materials used in the preparation of any unit dosage form should be pharmaceutically acceptable and substantially non-toxic in the amounts to be used.
- the active compounds can be incorporated into sustained release formulations and sustained release devices.
- the active compound may also be administered intravenously or intraperitoneally by infusion or injection.
- Aqueous solutions of the active compounds or salts thereof can be prepared, optionally mixed with nontoxic surfactants.
- Dispersions in glycerol, liquid polyethylene glycols, triacetin, and mixtures thereof and in oils can also be prepared. Under ordinary conditions of storage and use, these preparations contain a preservative to prevent the growth of microorganisms.
- compositions suitable for injection or infusion can include sterile aqueous solutions or dispersions of the active ingredient (optionally encapsulated in liposomes) containing the active ingredient suitable for extemporaneous preparation in sterile injectable or infusible solutions or dispersions. or sterile powder.
- the liquid carrier can be a solvent or liquid dispersion medium containing, for example, water, ethanol, polyol (eg, glycerol, propylene glycol, liquid polyethylene glycol, and the like), vegetable oils, nontoxic glycerides, and suitable mixtures thereof.
- Proper fluidity can be maintained, for example, by the formation of liposomes, by the maintenance of the desired particle size in the case of dispersions, or by the use of surfactants.
- Prevention of microorganisms can be brought about by various antibacterial and antifungal agents such as parabens, chlorobutanol, phenol, sorbic acid, thimerosal, and the like. In many cases it is preferred to include isotonic agents such as sugars, buffers or sodium chloride.
- Prolonged absorption of the injectable compositions can be brought about by the use of compositions delaying absorption, for example, aluminum monostearate and gelatin.
- Sterile injectable solutions are prepared by incorporating the active compound in the required amount in an appropriate solvent with various of the other ingredients enumerated above as required, followed by filtered sterilization.
- the preferred methods of preparation are vacuum drying and the freeze-drying techniques, which yield a powder of the active ingredient plus any additional required ingredients previously present in sterile-filtered solutions .
- Useful solid carriers include pulverized solids (eg, talc, clays, microcrystalline cellulose, silica, alumina, and the like).
- Useful liquid carriers include water, ethanol or ethylene glycol, or water-ethanol/ethylene glycol mixtures, in which the compounds of the present invention may be dissolved or dispersed at effective levels, optionally with the aid of non-toxic surfactants.
- Adjuvants eg, fragrances
- additional antimicrobial agents can be added to optimize properties for a given use.
- Thickeners such as synthetic polymers, fatty acids, fatty acid salts and esters, fatty alcohols, modified celluloses or modified inorganic materials can also be used with liquid carriers to form coatable pastes, gels, ointments , soap, etc., directly on the user's skin.
- unit dosage form which are physically discrete units containing unitary dosages, suitable for administration to the human and other mammalian bodies.
- the unit dosage form can be a capsule or tablet, or a number of capsules or tablets.
- the amount of active ingredient in a unit dose may vary or be adjusted from about 0.1 to about 1000 mg or more.
- milk liposomes such as milk liposomes, microspheres and nanospheres
- microparticle dispersion systems including polymeric micelles, nanoemulsion, submicroemuls
- Pharmaceutical preparations such as microcapsules, microspheres, liposomes and niosomes (also known as nonionic surfactant vesicles).
- the present invention also provides the compound described in any of the above technical solutions, its stereoisomer, its prodrug, or its pharmaceutically acceptable salt or pharmaceutically acceptable solvate or the above pharmaceutical composition Use in the preparation of a medicament for preventing and/or treating cancer or other diseases, or for modulating an immune response, or for modulating HPK1 kinase activity and/or function.
- the present invention also provides a method for preventing and/or treating cancer or other diseases, comprising administering to a subject in need thereof a preventive and/or therapeutically effective amount of the compound described in any of the above technical solutions, its stereoisomer body, its prodrug, or its pharmaceutically acceptable salt or pharmaceutically acceptable solvate or the above-mentioned pharmaceutical composition.
- the present invention also provides a method for regulating HPK1 kinase activity and/or function, comprising administering to a subject in need thereof a prophylactically and/or therapeutically effective amount of the compound described in any of the above technical solutions, its stereoisomer body, its prodrug, or its pharmaceutically acceptable salt or pharmaceutically acceptable solvate or the above-mentioned pharmaceutical composition.
- the present invention also provides a method for modulating an immune response, comprising administering to a subject in need thereof an effective amount of the compound, its stereoisomer, its prodrug, or its pharmacy An acceptable salt or a pharmaceutically acceptable solvate or a pharmaceutical composition of the above.
- the present invention also provides the compound described in any of the above technical solutions, its stereoisomer, its prodrug, or its pharmaceutically acceptable salt or pharmaceutically acceptable solvate or the above pharmaceutical composition , which is used to prevent and/or treat cancer or other diseases, or to modulate immune responses, or to modulate HPK1 kinase activity and/or function.
- the present invention also provides the compound described in any of the above technical solutions, its stereoisomer, its prodrug, or its pharmaceutically acceptable salt or pharmaceutically acceptable solvate in combination with PD-1, Application of PD-L1, CTLA-4, TIM-3, TGF ⁇ and its receptors, LAG3 antagonists or TLR4, TLR7, TLR8, TLR9, STING agonists in cancer immunotherapy.
- the present invention also provides the compound described in any of the above technical solutions, its stereoisomer, its prodrug, or its pharmaceutically acceptable salt or pharmaceutically acceptable solvate for immunization with CAR-T
- the use of combination therapy in cancer immunotherapy The use of combination therapy in cancer immunotherapy.
- the CAR-T immunotherapy refers to: chimeric antigen receptor T cell immunotherapy, the basic principle of which is to use the patient's own immune cells to remove cancer cells, which belongs to a type of cell therapy.
- the present invention also provides the compound described in any of the above technical solutions, its stereoisomers, its prodrugs, or its pharmaceutically acceptable salts or pharmaceutically acceptable solvates or the compounds comprising the compounds Use of a pharmaceutical composition in the preparation of a medicament for the prevention and/or treatment of cancer or other diseases.
- the present invention also provides a method for preventing and/or treating cancer or other diseases, comprising administering to a subject in need thereof a preventive and/or therapeutically effective amount of the above-mentioned compound or its stereoisomer, its prodrug, Its pharmaceutically acceptable salt or its pharmaceutically acceptable solvate or the above-mentioned pharmaceutical composition.
- the present invention also provides the above-mentioned compound or its stereoisomer, its prodrug, its pharmaceutically acceptable salt or its pharmaceutically acceptable solvate or the above-mentioned pharmaceutical composition, which are used for prevention and treatment /or to treat cancer or other diseases.
- modulating HPK1 kinase activity and/or function of the present invention is “inhibiting HPK1 kinase activity and/or function”.
- HPK1 kinase modulators of the invention are “HPK1 kinase inhibitors”.
- the "cancer or other disease” of the present invention is a “cancer or other disease associated with HPK1 kinase.”
- Cancers described in the present invention include lymphoma, sarcoma, lung cancer, non-small cell lung cancer, small cell lung cancer, gastric cancer, intestinal cancer, colon cancer, rectal cancer, lung adenocarcinoma, pancreatic cancer, breast cancer, prostate cancer, liver cancer, and skin cancer , epithelial cell carcinoma, glioblastoma, gastrointestinal stromal tumor, leukemia, nasopharyngeal carcinoma, glioblastoma, cervical cancer, ovarian cancer, bladder cancer, kidney cancer, thyroid cancer, vulvar cancer, anal cancer, Cancer of the penis, esophagus, biliary tract, head and neck, and hematological malignancies.
- CAR-T cells are cells used in CAR-T therapy (Chimeric Antigen Receptor T-Cell Immunotherapy).
- CAR-T therapy technicians activate T cells through genetic engineering technology, and install the positioning and navigation device CAR (Tumor Chimeric Antigen Receptor) to transform the ordinary "fighter” of T cells into a "super soldier”.
- CAR-T cells using their "positioning navigation device” CAR, specifically identify tumor cells in the body, and release a large number of various effectors through immune action. They can efficiently kill tumor cells, so as to achieve the purpose of treating malignant tumors.
- tumor immunotherapy drug should be understood in a broad sense, which not only includes traditional drugs, such as PD-1 monoclonal antibody, PD-L1 monoclonal antibody, CTLA-4 monoclonal antibody, TIM-3 monoclonal antibody, TGF ⁇ Monoclonal antibodies, LAG3 antagonists, TLR4 agonists, TLR7 agonists, TLR8 agonists, TLR9 agonists, STING agonists, also include "live drugs” that are different from traditional drugs, such as CAR-T cells.
- modulating an immune response refers to the improvement of any immunogenic response to an antigen.
- improvement of an immunogenic response to an antigen include enhanced maturation or migration of dendritic cells, improved activation of T cells (e.g., CD4 T cells, CD8 T cells), regulatory T cells (e.g., CD4 T cells, CD8 T cells) proliferation of T cells), regulation of B cell proliferation, improved survival of T cells and/or B cells, improved antigen presentation by antigen presenting cells (eg, dendritic cells), improved antigen clearance, modulation of cytokine production by T cells (eg , interleukin-2), improved resistance to prostaglandin E2-induced immunosuppression, and improved CD8 T cell priming and/or cytolytic activity.
- treating generally refers to obtaining a desired pharmacological and/or physiological effect.
- the effect may be prophylactic in terms of complete or partial prevention of the disease or its symptoms; and/or therapeutic in terms of partial or complete stabilization or cure of the disease and/or side effects due to the disease.
- Treatment encompasses any treatment of a disease in a patient, including: (a) prevention of disease or symptoms in a patient susceptible to a disease or condition but not yet diagnosed; (b) suppression of symptoms of disease, That is, preventing its development; or (c) alleviating the symptoms of the disease, ie, causing the disease or symptoms to regress.
- vertebrate refers to a mammal.
- Mammals include, but are not limited to, livestock (such as cattle), pets (such as cats, dogs, and horses), primates, mice, and rats.
- the mammal refers to a human.
- an “effective amount” refers to an amount effective to achieve the desired therapeutic or prophylactic effect at the necessary dose and time, or an amount effective to achieve the desired effect of modulating the immune response, or an amount effective to achieve the desired modulating HPK1 kinase activity and /or the amount of functional effect.
- a “therapeutically effective amount” of a substance/molecule of the invention may vary depending on factors such as the disease state, age, sex and weight of the individual and the ability of the substance/molecule to elicit a desired response in the individual.
- a therapeutically effective amount also encompasses an amount in which any toxic or detrimental consequences of the substance/molecule are outweighed by the therapeutically beneficial effects.
- a prophylactically effective amount refers to an amount effective at the dose and time necessary to achieve the desired prophylactic effect. Usually, but not necessarily, a prophylactically effective amount will be less than a therapeutically effective amount because the prophylactic dose is administered to the subject prior to the onset of the disease or at an early stage of the disease.
- a therapeutically effective amount of the drug reduces the number of cancer cells; shrinks the tumor size; inhibits (ie, slows to some extent, preferably stops) infiltration of cancer cells into surrounding organs; inhibits (ie, slows to some extent, preferably stops) ) tumor metastasis; some degree of inhibition of tumor growth; and/or some degree of alleviation of one or more symptoms associated with cancer.
- C1-C6 alkyl specifically refers to the independently disclosed methyl, ethyl, C3 alkyl, C4 alkyl, C5 alkyl and C6 alkyl, or the independently disclosed "C1-C4 alkyl", or Independently disclosed "C1-C3 alkyl”.
- C1-C6 alkyl refers to any straight or branched chain group containing 1 to 6 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl , tert-butyl, sec-butyl, n-pentyl, tert-amyl, n-hexyl, etc., or eg "C1-C4 alkyl", or eg "C1-C3 alkyl”.
- C1-C4 alkyl refers to any straight or branched chain group containing 1 to 4 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl base, tert-butyl, etc.
- C1-C3 alkyl refers to any straight or branched chain group containing 1 to 3 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, and the like.
- alkylene refers to a saturated divalent hydrocarbon radical obtained by removing two hydrogen atoms from a linear or branched saturated hydrocarbon radical.
- it can be "C1-C6 alkylene", “C1-C4 alkylene” or "C1-C3 alkylene”.
- Specific examples include, but are not limited to, methylene ( -CH2- ), ethylene ( -CH2 -CH2-), isopropylidene ( -CH2 - CH ( CH3 )-), Ethane-1,1-diyl, 2-methoxypropane-1,1-diyl, 2-hydroxypropane-1,1-diyl, 2-methyl-2-hydroxypropane-1,1- Two bases and so on.
- C1-C6 alkylene refers to any linear or branched saturated hydrocarbon group containing 1 to 6 carbon atoms, a saturated divalent hydrocarbon group obtained by removing two hydrogen atoms, such as methylene , ethylene, n-propylene, isopropylidene, etc.
- C1-C4 alkylene refers to any linear or branched saturated hydrocarbon group containing 1 to 4 carbon atoms, a saturated divalent hydrocarbon group obtained by removing two hydrogen atoms, such as methylene , ethylene, n-propylene, isopropylidene, etc.
- C1-C3 alkylene refers to any linear or branched saturated hydrocarbon group containing 1 to 3 carbon atoms, a saturated divalent hydrocarbon group obtained by removing two hydrogen atoms, such as methylene , ethylene, n-propylene, isopropylidene, etc.
- C3-C8 cycloalkyl refers to a hydrocarbon with a 3-8 membered monocyclic ring system having a saturated ring, and the C3-C8 cycloalkyl can be cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like.
- C3-C6 cycloalkyl refers to a hydrocarbon having a 3-6 membered monocyclic ring system with a saturated ring, and the C3-C6 cycloalkyl can be cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like.
- cyano refers to a -CN residue.
- nitro refers to the -NO 2 group.
- Heteroatoms are N, O or S.
- Halogen is fluorine, chlorine, bromine and iodine, preferably fluorine, chlorine and bromine.
- alkoxy refers to any of the above-mentioned alkyl groups (eg C1-C6 alkyl, C1-C4 alkyl, C1-C3 alkyl, etc.), cycloalkane group (eg, C3-C8 cycloalkyl, C3-C6 cycloalkyl), which is attached to the rest of the molecule through an oxygen atom (-O-).
- alkyl groups eg C1-C6 alkyl, C1-C4 alkyl, C1-C3 alkyl, etc.
- cycloalkane group eg, C3-C8 cycloalkyl, C3-C6 cycloalkyl
- heteroaryl refers to an aromatic heterocycle, typically a 5-, 6-, 7-, 8-membered heterocycle having 1 to 3 heteroatoms selected from N, O or S; heteroaryl
- the base ring can optionally be further fused or attached to aromatic and non-aromatic carbocyclic and heterocyclic rings.
- Non-limiting examples of such heteroaryl groups are eg pyridyl, pyrazinyl, pyrimidinyl, pyridazinyl, indolyl, imidazolyl, thiazolyl, isothiazolyl, thioxazolyl, pyrrolyl, benzene yl-pyrrolyl, furyl, phenyl-furyl, oxazolyl, isoxazolyl, pyrazolyl, thienyl, benzofuranyl, benzothienyl, benzol,3-dioxolane (benzodioxin), isoindoline, benzimidazolyl, indazolyl, quinolinyl, isoquinolinyl, 1,2,3-triazolyl, 1-phenyl-1, 2,3-triazolyl, 2,3-indoline, 2,3-dihydrobenzofuranyl, 2,3-dihydrobenz
- heteroaryl may be, for example, thiazolyl, isothiazolyl, thioxazolyl, pyrrolyl, oxazolyl, isoxazolyl, pyrazolyl, imidazolyl, furyl, thienyl, and the like.
- halo-C1-C6 alkyl refers to one or more hydrogen atoms in the alkyl or cycloalkyl group Substituted by halogen atoms, such as fluorine, chlorine, bromine.
- the alkyl or cycloalkyl is as defined above.
- the term "halo C1 - C6 alkyl” is preferably fluoro, eg -CF3 , -CHF2 , -CH2F , -CH2CH2F , -CH2CHF2 , -CH2CHF2 , -CH2 CF 3 etc.
- Fluorine-containing alkyl refers to a group in which the alkyl backbone is substituted with one or more fluorine groups, for example, monofluoromethyl, difluoroethyl, trifluoromethyl, and the like.
- the alkyl group is as defined above.
- C1-C6 fluorine-containing alkyl refers to a group in which the C1-C6 alkyl backbone is substituted with one or more fluorine groups, for example, monofluoromethyl, difluoroethyl, trifluoromethyl and the like.
- C1-C3 fluoroalkyl refers to a group in which the C1-C3 alkyl backbone is substituted with one or more fluoro groups, for example, monofluoromethyl, difluoroethyl, trifluoromethyl Base et al.
- Fluorine-containing cycloalkyl refers to a group in which the cycloalkyl backbone is substituted with one or more fluorine groups, for example, 2-fluoro-cyclopropyl, 3-fluoro-cyclopropyl, 2,3-difluoro Cyclopropyl etc.
- the cycloalkyl group is as defined above.
- C3-C8 fluorine-containing cycloalkyl refers to a group in which the C3-C8 cycloalkyl backbone is substituted with one or more fluorine groups, for example, 2-fluoro-cyclopropyl, 3-fluoro-cyclopropyl base, 2,3-difluorocyclopropyl, etc.
- C3-C6 fluorine-containing cycloalkyl refers to a group in which the C3-C6 cycloalkyl backbone is substituted with one or more fluorine groups, for example, 2-fluoro-cyclopropyl, 3-fluoro -Cyclopropyl, 2,3-difluorocyclopropyl, etc.
- C1-C6 heteroatom-containing alkyl refers to a group formed by replacing one or more carbon atoms in the C1-C6 alkyl skeleton with one or more heteroatoms, such as "C1-C6 oxygen-containing "alkyl” or "C1-C6 sulfur-containing alkyl", etc., for example, Wait.
- Oxygen-containing alkyl refers to a group in which the alkyl backbone is substituted with one or more alkoxy groups, eg, methoxyethyl, methoxyethoxymethyl, and the like.
- C1-C6 oxyalkyl refers to a group in which the C1-C6 alkyl backbone is substituted with one or more C1-C6 alkoxy groups, for example, methoxyethyl, methoxyethoxy methyl, etc.
- a C1-C3 oxyalkyl group refers to a group in which the C1-C3 alkyl backbone is substituted with one or more C1-C6 alkoxy groups.
- C3-C8 heteroatom-containing cycloalkyl or "C3-C6 heteroatom-containing cycloalkyl” means that one or more carbon atoms in the C3-C8 cycloalkyl skeleton or C3-C6 cycloalkyl skeleton are The group formed by the substitution of one or more heteroatoms, for example, can be "C3-C8 oxygen-containing cycloalkyl", “C3-C6 oxygen-containing cycloalkyl”, “C3-C8 sulfur-containing cycloalkyl” or " C3-C6 sulfur-containing cycloalkyl”, specific examples are pyrrolidine, imidazolidine, pyrazolidine, thiazolidine, piperidine, piperazine, morpholine, morpholinyl, thiomorpholinyl and the like.
- C3-C8 oxygen-containing cycloalkyl refers to a group in which the C3-C8 cycloalkyl backbone is substituted with one or more C1-C6 alkoxy groups.
- C3-C8 cycloalkyl or C1-C6 alkoxy is as described above.
- C3-C6 oxygen-containing cycloalkyl refers to a group in which the C3-C6 cycloalkyl backbone is substituted with one or more C1-C6 alkoxy groups. Among them, the definition of C3-C6 cycloalkyl or C1-C6 alkoxy is as described above.
- heterocycle refers to a 3-, 4-, 5-, 6-, 7-, or 8-membered saturated or partially unsaturated carbocyclic ring in which one or more carbon atoms are replaced by heteroatoms such as nitrogen, oxygen, and sulfur alternative.
- heterocycles are, for example, pyran, pyrrolidine, pyrroline, imidazoline, imidazolidine, pyrazolidine, pyrazoline, thiazoline, thiazolidine, dihydrofuran, tetrahydrofuran, 1,3-dihydrofuran Oxolane, piperidine, piperazine, morpholine, morpholinyl, tetrahydropyrrolyl, thiomorpholinyl and the like.
- 6-membered heterocycle refers to a 6-membered saturated or partially unsaturated carbocyclic ring in which one or more carbon atoms are replaced by heteroatoms such as nitrogen, oxygen, and sulfur.
- Non-limiting examples of 6-membered heterocyclyl groups are, for example, pyran, piperidine, piperazine, morpholine, morpholinyl, thiomorpholinyl, and the like.
- 5-membered heterocycle refers to a 5-membered saturated or partially unsaturated carbocyclic ring in which one or more carbon atoms are replaced by heteroatoms such as nitrogen, oxygen, and sulfur.
- Non-limiting examples of 5-membered heterocyclyl groups are, for example, pyrrolidine, pyrroline, imidazoline, imidazolidine, pyrazolidine, pyrazoline, thiazoline, thiazolidine, 1,3-dioxolane, and the like.
- any group whose name is a compound name such as "HO-C1-C6 alkyl” or "R a R b N-C1-C6 alkyl"
- any group whose name is a compound name should refers to moieties conventionally derived therefrom such as constructed from hydroxy-substituted C1-C6 alkyl or from R a R b N-substituted C1-C6 alkyl, wherein C1-C6 alkyl is as defined above .
- Other similar compound names can be understood with reference to the foregoing.
- R 1 is selected from , if L is a direct bond, the structural formula of R 1 is Other similar definitions can be understood with reference to the foregoing.
- prodrug refers to a derivative that can be hydrolyzed, oxidized, or otherwise reacted under biological conditions (in vitro or in vivo) to provide a compound of the present invention. Prodrugs only undergo this reaction under biological conditions to become the active compound, or they are active in their unreacted form. Prodrugs can generally be prepared using well-known methods, such as those described in Burger's Medicinal Chemistry and Drug Discovery (1995) 172-178, 949-982 (Edited by Manfred E. Wolff, 5th ed.).
- examples of the term "pharmaceutically acceptable salts of compounds” are organic acid addition salts formed from organic acids that form pharmaceutically acceptable anions, including but not limited to formate, acetate, Propionate, Benzoate, Maleate, Fumarate, Succinate, Tartrate, Citrate, Ascorbate, Alpha-Ketoglutarate, Alpha-Glycerophosphate, Alkyl Sulfonate acid salt or aryl sulfonate; preferably, the alkyl sulfonate is methyl sulfonate or ethyl sulfonate; the aryl sulfonate is benzene sulfonate or p-toluene sulfonate .
- Suitable inorganic salts may also be formed including, but not limited to, hydrochloride, hydrobromide, hydroiodide, nitrate, bicarbonate and carbonate, sulfate or phosphate, and the like.
- compositions can be obtained using standard procedures well known in the art, eg, by reacting a sufficient amount of a basic compound with a suitable acid to provide a pharmaceutically acceptable anion.
- Thin-layer chromatography was performed on silica gel GF254 precoated plates (Qingdao Ocean Chemical Factory). Column chromatography on silica gel (300-400 mesh, Yantai Zhifu District Huangwu Silica Silica Development Reagent Factory) at medium pressure or by using an ISCO Combiflash Rf200 rapid purification system with prepacked silica cartridges (ISCO or Welch) Chromatographic separation. The components were developed by UV light (wavelength 254 nm) and by iodine vapor.
- Electrospray (ESI) mass spectra were acquired on a Finnigan LCQ ion trap.
- HPLC-UV-MS analysis for evaluating compound purity was performed by combining ion trap MS equipment with HPLC system SSP4000 (Thermo Separation Products) equipped with autosampler LC Pal (CTC Analytics) and UV6000LP diode array Detector (UV detection 215-400 nm). Device control, data acquisition and processing were performed with Xcalibur 1.2 software (Finnigan). HPLC chromatography was performed at room temperature and a flow rate of 1 mL/min using a Waters X Terra RP 18 column (4.6 x 50 mm; 3.5 ⁇ m).
- Mobile phase A was ammonium acetate 5mM buffer (using acetic acid to give pH 5.5):acetonitrile 90:10, mobile phase B ammonium acetate 5mM buffer (using acetic acid to give pH 5.5):acetonitrile 10:90; gradient 0 to 100% B This was done for 7 minutes, then 100% B was held for 2 minutes before re-equilibration.
- W, R 3 , Z 1 , Z 2 , Z 3 , Z 4 , Z 5 , Z 6 , and Z 7 are as described above.
- 5-Amino-6-nitro group was obtained by the reaction of 6-nitroquinoxaline (cas: 6639-87-8, Bide, Shanghai) and hydroxylamine hydrochloride (cas: 5470-11-1, Annagy, Shanghai) Quinoxaline, converted into 5-chloro-6-nitroquinoxaline, and further reacted with mesylmethylamide (cas: 1184-85-6, Bi De, Shanghai) to obtain The final reduction of nitro derived.
- the following intermediates were obtained in a similar manner:
- the raw materials involved are: methylamine (cas: 74-89-5, Annagy, Shanghai), ethylamine (cas: 75-04-7, Aladdin, Shanghai), cyclopropylamine (cas: 765- 30-0, Annagi, Shanghai), trifluoromethanesulfonyl chloride (cas: 421-83-0, Aladdin, Shanghai), ethylsulfonyl chloride (cas: 594-44-5, Annagi, Shanghai) , isopropylsulfonyl chloride (cas: 10147-37-2, TCI, Shanghai), cyclopropylsulfonyl chloride (cas: 139631-62-2, Annagy, Shanghai), methylsulfonyl chloride (cas: 124- 63-0, West Asia Reagents, Shandong).
- the raw materials involved are:
- Acetaldehyde (cas: 75-07-0, Sinopharm Reagent, Shanghai), bromoisopropane (cas: 75-26-3, McLean, Shanghai), bromocyclopropane (cas: 4333-56-6, Bi obtained, Shanghai), 2-dimethylaminochloroethane hydrochloride (cas: 4584-46-7, Aikang, Jiangsu), N-Boc-3-hydroxyazetidine (cas: 141699-55- 0, Bide, Shanghai), N-Boc-3-hydroxypyrrolidine (cas: 103057-44-9, Bide, Shanghai), tert-butyl 4-hydroxyazepane-1-carboxylate (cas : 478832-21-2, Bide, Shanghai), Tetrahydropyran-4-ol (cas: 2081-44-9, Bide, Shanghai), Tetrahydrothiopyran-4-ol (cas: 29683-23 -6, Bide, Shanghai), tetrahydro-2H-thiopyran-4-ol-1
- the raw materials involved are: 4-dimethylaminopiperidine (cas: 50533-97-6, Shaoyuan, Shanghai), 4-methoxypiperidine (cas: 4045-24-3, Bide, Shanghai), N-methylhomopiperazine (cas: 4318-37-0, Bide, Shanghai), tetrahydropyrrole (cas: 123-75-1, Aladdin, Shanghai), 3-hydroxypyrrolidine (cas: 40499- 83-0, Bide, Shanghai), 3-N,N-dimethylaminopyrrolidine (cas: 64021-83-6, TCI, Shanghai), azetidine (cas: 503-29-7, Bide, Shanghai), azetidine-3-ol (cas: 45347-82-8, Bide, Shanghai), N,N-dimethylazeridin-3-amine (cas: 138022-85 -2, Bide, Shanghai), 3-Boc-aminoazetidine (cas: 91188-13-5, Bide, Shanghai), 2-bromoethanol (cas: 540-5
- the first step Compound 1 (500 mg, 2.26 mmol) was dissolved in DMF (5 mL), NaH (60% content, dispersed in liquid paraffin, 180 mg, 4.52 mmol) was added in batches at 0 °C, and 2 , 4-Dichloro-5-bromopyrimidine (618 mg, 2.71 mmol), the reaction was carried out by heating for 1 hour, and the completion of the reaction was detected by TLC and LCMS. 100 mL of water was added, a solid was precipitated, filtered, and dried to obtain compound 2 (371 mg), which was directly used in the next step.
- the second step Compound 2 (41.3 mg, 0.1 mmol), compound 3 (18.0 mg, 0.1 mmol) and methanesulfonic acid (19 ⁇ L, 0.3 mmol) were heated in t-BuOH (2 mL) at 80°C for 4 h, and detected by TLC and LCMS The reaction is complete. After cooling, the reaction mixture was concentrated, purified by silica gel column (eluted with dichloromethane/methanol), and then purified by preparative HPLC (with 0.35% trifluoroacetic acid in water and methanol as mobile phase) to obtain compound I-1 ( 25.8 mg).
- the first step Compound 2 (82.5 mg, 0.2 mmol), compound 4 (53.2 mg, 0.2 mmol) and diisopropylethylamine (66 ⁇ L, 0.4 mmol) were heated in DMSO (2 mL) at 100 ° C for 12 h, TLC and The reaction was completed by LCMS detection. After cooling, add water (50 mL) to dilute, extract with DCM (30 mL ⁇ 3), combine the organic phases, wash with saturated brine (50 mL ⁇ 2), dry over anhydrous Na 2 SO 4 , filter and concentrate, and the residue is purified by silica gel column (with Dichloromethane/methanol elution) to give compound 5 (91 mg).
- the first step compound 5 (0.062 mmol, 40 mg), vinylboronic acid pinacol ester (0.186 mmol, 31 ⁇ L), PdCl 2 (dppf) ⁇ CH 2 Cl 2 (0.0062 mmol, 5.0 mg), Na 2 CO 3 ( 0.186 mmol, 19.8 mg) was dispersed in 1,4-dioxane (1 mL) and water (0.5 mL), and the reaction system was heated at 100 degrees Celsius for 4 h after replacing nitrogen.
- HPK1 The enzymatic activity of HPK1 was tested by ADP-Glo kit (Cat#V9102) of Promega Company, and the experimental buffer conditions were: 40mM HEPES, 150mM NaCl, 20mM MgCl 2 , pH 7.5.
- the experimental conditions were 500 nM HPK1 (MAP4K1) kinase incubated with 10 ⁇ M ATP, 1 ⁇ M MBP Protein kinase substrate (SignalChem, Lot #E3237-5) and small molecule compounds for 90 minutes. The initial concentration of small molecule compounds was 10 ⁇ M, and there were 8 concentration points in 3-fold dilution.
- Luminescence intensity data were read by Perkin Elmer's Envision microplate reader. The experimental results are shown in the table below.
- ++++ represents IC 50 ⁇ 100 nM; +++ represents 100 nM ⁇ IC 50 ⁇ 500 nM; ++ represents 500 nM ⁇ IC 50 ⁇ 2000 nM.
- the compounds of the present invention have very good HPK1 kinase inhibitory activity.
Abstract
Description
序列号 | 测试结果 | 序列号 | 测试结果 |
I-1 | ++++ | II-71 | +++ |
I-2 | +++ | II-72 | ++++ |
I-3 | ++++ | II-73 | ++++ |
I-4 | ++++ | II-74 | +++ |
I-5 | +++ | II-75 | ++++ |
I-6 | ++++ | II-76 | +++ |
I-7 | ++++ | II-77 | +++ |
I-8 | +++ | II-78 | +++ |
I-12 | ++++ | II-79 | ++ |
I-13 | +++ | II-80 | +++ |
I-14 | +++ | II-81 | ++ |
I-15 | ++ | II-82 | +++ |
I-18 | +++ | II-83 | +++ |
I-19 | ++ | II-84 | +++ |
I-20 | +++ | II-85 | ++++ |
I-21 | ++ | III-1 | ++++ |
I-23 | ++ | III-3 | +++ |
I-24 | ++ | III-4 | ++++ |
I-30 | +++ | III-6 | ++++ |
I-33 | +++ | III-7 | ++ |
I-34 | ++ | III-14 | ++ |
I-35 | ++ | III-18 | ++++ |
I-36 | +++ | III-19 | ++ |
I-37 | ++ | III-20 | ++ |
I-38 | ++ | III-21 | ++ |
I-39 | +++ | III-23 | ++ |
I-43 | +++ | III-24 | ++ |
I-44 | ++ | III-25 | +++ |
I-45 | ++ | III-26 | ++ |
I-46 | +++ | III-31 | ++ |
I-47 | +++ | III-33 | ++ |
I-48 | ++ | III-34 | ++ |
I-49 | +++ | III-35 | +++ |
I-50 | ++++ | III-36 | +++ |
I-51 | +++ | III-37 | ++ |
I-52 | +++ | III-38 | ++ |
I-53 | ++ | III-39 | ++++ |
I-54 | ++++ | III-40 | ++++ |
I-55 | ++++ | III-41 | ++++ |
I-56 | +++ | III-42 | ++ |
I-57 | ++++ | III-52 | +++ |
I-58 | +++ | III-53 | +++ |
I-59 | +++ | III-55 | +++ |
I-60 | +++ | III-56 | ++ |
I-62 | +++ | III-57 | +++ |
I-63 | ++ | III-58 | ++++ |
I-66 | ++++ | III-59 | +++ |
I-67 | +++ | III-60 | +++ |
II-2 | +++ | III-61 | +++ |
II-3 | ++++ | III-62 | +++ |
II-4 | ++++ | III-63 | +++ |
II-5 | ++++ | IV-1 | +++ |
II-6 | ++++ | IV-3 | +++ |
II-7 | +++ | IV-4 | ++++ |
II-8 | ++++ | IV-5 | +++ |
II-12 | +++ | IV-6 | ++ |
II-14 | +++ | IV-7 | ++ |
II-15 | ++ | IV-14 | ++++ |
II-16 | ++++ | IV-15 | ++ |
II-17 | +++ | IV-18 | ++++ |
II-18 | ++++ | IV-19 | ++ |
II-20 | ++ | IV-20 | +++ |
II-21 | ++ | IV-21 | ++++ |
II-22 | ++ | IV-23 | +++ |
II-31 | +++ | IV-24 | +++ |
II-32 | +++ | IV-25 | ++++ |
II-33 | ++++ | IV-26 | ++ |
II-34 | +++ | IV-28 | ++ |
II-40 | ++++ | IV-30 | +++ |
II-43 | ++++ | IV-31 | ++++ |
II-44 | ++++ | IV-37 | ++++ |
II-45 | ++++ | IV-38 | +++ |
II-46 | +++ | IV-39 | ++++ |
II-47 | +++ | IV-40 | +++ |
II-49 | ++ | IV-41 | +++ |
II-52 | ++ | IV-42 | ++++ |
II-55 | +++ | IV-43 | +++ |
II-56 | ++ | IV-44 | ++++ |
II-57 | ++++ | IV-54 | +++ |
II-58 | ++++ | IV-55 | ++ |
II-59 | ++++ | IV-56 | ++ |
II-60 | ++++ | IV-57 | ++ |
II-61 | ++++ | IV-58 | ++ |
II-62 | ++ | IV-59 | ++++ |
II-63 | ++++ | IV-60 | ++++ |
II-64 | +++ | IV-61 | ++++ |
II-65 | +++ | IV-62 | ++++ |
II-66 | +++ | IV-63 | ++++ |
II-67 | ++ | IV-64 | +++ |
II-68 | +++ | IV-65 | ++++ |
II-69 | ++++ | IV-66 | ++++ |
II-70 | ++++ | IV-67 | +++ |
Claims (13)
- 以下通式化合物:或所述化合物的立体异构体、其前药、其药学上可接受的盐或其药学上可接受的溶剂合物,其中:各L独立地选自直接键、C1-C6亚烷基;优选地,各L独立地选自直接键、亚甲基、亚乙基;各Y独立地选自氢、C1-C6烷基、C3-C6环烷基、HO-C1-C6烷基、R aR bN-C1-C6烷基;优选地,各Y独立地选自氢、甲基、乙基、异丙基、环丙基、2-羟基乙基、2-(N,N-二甲基氨基)乙基;各Z独立地选自氢、羟基、C1-C6烷基、C1-C6烷氧基、C3-C6环烷基、C3-C6环烷基-O-、HO-C1-C6烷基、R aR bN-、R aR bN-C1-C6烷基;优选地,各Z独立地选自氢、羟基、C1-C6烷基、C1-C6烷氧基、R aR bN-;更优选地,各Z独立地选自氢、羟基、C1-C6烷氧基、R aR bN-;最优选地,各Z独立地选自氢、羟基、氨基、N,N-二甲基氨基、甲氧基;R a、R b各自独立地选自氢、C1-C6烷基;优选地,R a、R b各自独立地选自H、甲基;X 1,X 2,X 3,X 4各自独立地选自C,CH,CH 2,N,NH,O,S;优选地,X 1,X 2,X 3,X 4各自独立地选自C,CH,N,O,S;更优选地,X 1,X 2,X 3,X 4各自独立地选自C,CH,N,S;Y 1,Y 2,Y 3,Y 4各自独立地选自C,CH,CH 2,N,NH,O,S;优选地,Y 1,Y 2,Y 3,Y 4各自独立地选自C,CH,N,O,S;更优选地,Y 1,Y 2,Y 3,Y 4各自独立地选自C,CH,N;R 2选自:2) 其中,Z 3、Z 4各自独立地选自氢,C1-C6烷基,卤代C1-C6烷基,C3-C6环烷基,卤代C3-C6环烷基,且Z 4不为氢;优选地,Z 3、Z 4各自独立地选自氢,C1-C6烷基,卤代C1-C6烷基,C3-C6环烷基,且Z 4不为氢;更优选地,Z 3、Z 4各自独立地选自氢,甲基,乙基,异丙基,环丙基,-CF 3,且Z 4不为氢;或者优选地,Z 3选自氢,C1-C6烷基,C3-C6环烷基;或者优选地,Z 4选自C1-C6烷基,卤代C1-C6烷基,C3-C6环烷基;或者更优选地,Z 3选自氢,甲基,乙基,环丙基;或者更优选地,Z 4选自甲基,乙基,异丙基,-CF 3,环丙基;3) 其中,Z 5选自C1-C6烷基,卤代C1-C6烷基,C3-C8环烷基,C1-C6含杂原子烷基,C3-C8含杂原子环烷基;优选地,Z 5选自C1-C6烷基、C3-C6环烷基;更优选地,Z 5选自甲基,乙基,异丙基,环丙基;4) 其中,Z 6、Z 7各自独立地选自氢,C1-C6烷基,卤代C1-C6烷基,C3-C6环烷基,卤代C3-C6环烷基,或者,Z 6、Z 7与它们共同连接的N原子一起形成取代或未取代的含1~2个杂原子的4-8元杂环,所述取代基选自卤素,C1-C6烷基,C3-C8环烷基;优选地,Z 6、Z 7各自独立地选自氢,C1-C6烷基,C3-C6环烷基;或者优选地,Z 6、Z 7与它们共同连接的N原子一起形成含1-2个杂原子的4-8元杂环;更优选地,Z 6、Z 7各自独立地选自氢,C1-C6烷基,C3-C6环烷基,且Z 6、Z 7不同时为氢;或者更优选地,Z 6、Z 7与它们共同连接的N原子一起形成含1-2个(优选1个)杂原子(优选氮原子)的4-6元饱和杂环;进一步优选地,Z 6、Z 7各自独立地选自氢,甲基,乙基,异丙基,环丙基,且Z 6、Z 7不同时为氢;或者进一步优选地,Z 6、Z 7与它们共同连接的N原子一起形成 (优选形成 );最优选地,Z 6为氢,甲基;Z 7选自甲基,乙基,异丙基,环丙基;或者,Z 6、Z 7与它们共同连接的N原子一起形成R 3选自氢,卤素,卤代C1-C6烷基(例如,三氟甲基),氰基,硝基,C1-C6烷基(例如,甲基,乙基),C1-C6烷氧基(例如,甲氧基),C3-C6环烷基(例如,环丙基),C2-C6烯基(例如,乙烯基);优选地,R 3选自氢,氟,氯,溴,三氟甲基,氰基,硝基,甲基,乙基,甲氧基,环丙基,乙烯基;R 4、R 5各自独立地选自氢、氟、氯、溴、碘、C1-C6烷基,且R 4、R 5不同时为氢;优选地,R 4、R 5各自独立地选自氢、氟、氯、甲基,且R 4、R 5不同时为氢;更优选地,R 4选自氢、氟、氯、甲基,R 5选自氢、甲基,且R 4、R 5不同时为氢。
- 权利要求1的化合物,或所述化合物的立体异构体、其前药、其药学上可接受的盐或其药学上可接受的溶剂合物,其中,Z 1、Z 2各自独立地选自C1-C6烷基,C3-C8环烷基;优选地,Z 1、Z 2各自独立地选自C1-C6烷基;更优选地,Z 1、Z 2为甲基;各L独立地选自直接键、C1-C6亚烷基;优选地,各L独立地选自直接键、亚甲基、亚乙基;各Y独立地选自氢、C1-C6烷基、C3-C6环烷基、HO-C1-C6烷基、R aR bN-C1-C6烷基;优选地,各Y独立地选自氢、甲基、乙基、异丙基、环丙基、2-羟基乙基、2-(N,N-二甲基氨基)乙基;各Z独立地选自氢、羟基、C1-C6烷基、C1-C6烷氧基、C3-C6环烷基、C3-C6环烷基-O-、HO-C1-C6烷基、R aR bN-、R aR bN-C1-C6烷基;优选地,各Z独立地选自氢、羟基、C1-C6烷基、C1-C6烷氧基、R aR bN-;更优选地,各Z独立地选自氢、羟基、C1-C6烷氧基、R aR bN-;最优选地,各Z独立地选自氢、羟基、氨基、N,N-二甲基氨基、甲氧基;优选地,R 1为 时,L选自直接键、C1-C6亚烷基,优选选自直接键、亚甲基、亚乙基;Y选自氢、C1-C6烷基、C3-C6环烷基、HO-C1-C6烷基、R aR bN-C1-C6烷基,优选选自氢、甲基、乙基、异丙基、环丙基、2-羟基乙基、2-(N,N-二甲基氨基)乙基;R a、R b各自独立地选自氢、C1-C6烷基;优选地,R a、R b各自独立地选自H、甲基;X 1,X 2,X 3,X 4各自独立地选自C,CH,CH 2,N,NH,O,S;优选地,X 1,X 2,X 3,X 4各自独立地选自C、CH,N,O,S;更优选地,X 1,X 2,X 3,X 4各自独立地选自C,CH,N,S;Y 1,Y 2,Y 3,Y 4各自独立地选自C,CH,CH 2,N,NH,O,S;优选地,Y 1,Y 2,Y 3,Y 4各自独立地选自C,CH,N,O,S;更优选地,Y 1,Y 2,Y 3,Y 4各自独立地选自C,CH,N;R 3选自氢,卤素,卤代C1-C6烷基(例如,三氟甲基),氰基,硝基,C1-C6烷基(例如,甲基,乙基),C1-C6烷氧基(例如,甲氧基),C3-C6环烷基(例如,环丙基),C2-C6烯基(例如,乙烯基);优选地,R 3选自氢,卤素,C1-C6烷基(例如,甲基,乙基),C3-C6环烷基(例如,环丙基),C2-C6烯基(例如,乙烯基);更优选地,R 3选自氢,氟,氯,溴,甲基,乙基,环丙基,乙烯基;R 4、R 5各自独立地选自氢、氟、氯、溴、碘、C1-C6烷基,且R 4、R 5不同时为氢;优选地,R 4、R 5各自独立地选自氢、氟、氯,且R 4、R 5不同时为氢;更优选地,R 4为氯,R 5为氢。
- 权利要求1的化合物,或所述化合物的立体异构体、其前药、其药学上可接受的盐或其药学上可接受的溶剂合物,其中,Z 3、Z 4各自独立地选自氢,C1-C6烷基,卤代C1-C6烷基,C3-C6环烷基,卤代C3-C6环烷基,且Z 4不为氢;优选地,Z 3、Z 4各自独立地选自氢,C1-C6烷基,卤代C1-C6烷基,C3-C6环烷基,且Z 4不为氢;更优选地,Z 3、Z 4各自独立地选自氢,甲基,乙基,异丙基,环丙基,-CF 3,且Z 4不为氢;或者优选地,Z 3选自氢,C1-C6烷基,C3-C6环烷基;或者优选地,Z 4选自C1-C6烷基,卤代C1-C6烷基,C3-C6环烷基;或者更优选地,Z 3选自氢,甲基,乙基,环丙基;或者更优选地,Z 4选自甲基,乙基,异丙基,-CF 3,环丙基;各L独立地选自直接键、C1-C6亚烷基;优选地,各L独立地选自直接键、亚甲基、亚乙基;各Y独立地选自氢、C1-C6烷基、C3-C6环烷基、HO-C1-C6烷基、R aR bN-C1-C6烷基;优选地,各Y独立地选自氢、甲基、乙基、异丙基、环丙基、2-羟基乙基、2-(N,N-二甲基氨基)乙基;各Z独立地选自氢、羟基、C1-C6烷基、C1-C6烷氧基、C3-C6环烷基、C3-C6环烷基-O-、HO-C1-C6烷基、R aR bN-、R aR bN-C1-C6烷基;优选地,各Z独立地选自氢、羟基、C1-C6烷基、C1-C6烷氧基、R aR bN-;更优选地,各Z独立地选自氢、羟基、C1-C6烷氧基、R aR bN-;最优选地,各Z独立地选自氢、羟基、氨基、N,N-二甲基氨基、甲氧基;优选地,R 1为 时,L选自直接键、C1-C6亚烷基,优选选自直接键、亚甲基、亚乙基;Y选自氢、C1-C6烷基、C3-C6环烷基、HO-C1-C6烷基、R aR bN-C1-C6烷基,优选选自氢、甲基、乙基、异丙基、环丙基、2-羟基乙基、2-(N,N-二甲基氨基)乙基;R a、R b各自独立地选自氢、C1-C6烷基;优选地,R a、R b各自独立地选自H、甲基;X 1,X 2,X 3,X 4各自独立地选自C,CH,CH 2,N,NH,O,S;优选地,X 1,X 2,X 3,X 4各自独立地选自C、CH,N,O,S;更优选地,X 1,X 2,X 3,X 4各自独立地选自C,CH,N,S;最优选地,X 1,X 2,X 3,X 4各自独立地选自CH,N;Y 1,Y 2,Y 3,Y 4各自独立地选自C,CH,CH 2,N,NH,O,S;优选地,Y 1,Y 2,Y 3,Y 4各自独立地选自C,CH,N,O,S;更优选地,Y 1,Y 2,Y 3,Y 4各自独立地选自C,CH,N;R 3选自氢,卤素,卤代C1-C6烷基(例如,三氟甲基),氰基,硝基,C1-C6烷基(例如,甲基,乙基),C1-C6烷氧基(例如,甲氧基),C3-C6环烷基(例如,环丙基),C2-C6烯基(例如,乙烯基);优选地,R 3选自氢,卤素,卤代C1-C6烷基(例如,三氟甲基),氰基,硝基,C1-C6烷基(例如,甲基),C1-C6烷氧基(例如,甲氧基),C3-C6环烷基(例如,环丙基);更优选地,R 3选自氢,氟,氯,溴,三氟甲基,氰基,硝基,甲基,甲氧基,环丙基;R 4、R 5各自独立地选自氢、氟、氯、溴、碘、C1-C6烷基,且R 4、R 5不同时为氢;优选地,R 4、R 5各自独立地选自氢、氟、氯、甲基,且R 4、R 5不同时为氢;更优选地,R 4选自氢、氟、氯、甲基,R 5选自H、甲基,且R 4、R 5不同时为氢。
- 权利要求1的化合物,或所述化合物的立体异构体、其前药、其药学上可接受的盐或其药学上可接受的溶剂合物,其中,Z 5选自C1-C6烷基,卤代C1-C6烷基,C3-C8环烷基,C1-C6含杂原子烷基,C3-C8含杂原子环烷基;优选地,Z 5选自C1-C6烷基、C3-C8环烷基;更优选地,Z 5选自C1-C6烷基、C3-C6环烷基;最优选地,Z 5选自甲基,乙基,异丙基、环丙基;各L独立地选自直接键、C1-C6亚烷基;优选地,各L独立地选自直接键、亚甲基、亚乙基;各Y独立地选自氢、C1-C6烷基、C3-C6环烷基、HO-C1-C6烷基、R aR bN-C1-C6烷基;优选地,各Y独立地选自氢、甲基、乙基、异丙基、环丙基、2-羟基乙基、2-(N,N-二甲基氨基)乙基;各Z独立地选自氢、羟基、C1-C6烷基、C1-C6烷氧基、C3-C6环烷基、C3-C6环烷基-O-、HO-C1-C6烷基、R aR bN-、R aR bN-C1-C6烷基;优选地,各Z独立地选自氢、羟基、C1-C6烷基、C1-C6烷氧基、R aR bN-;更优选地,各Z独立地选自氢、羟基、C1-C6烷氧基、R aR bN-;最优选地,各Z独立地选自氢、羟基、氨基、N,N-二甲基氨基、甲氧基;优选地,R 1为 时,L选自直接键、C1-C6亚烷基,优选选自直接键、亚甲基、亚乙基;Y选自氢、C1-C6烷基、C3-C6环烷基、HO-C1-C6烷基、R aR bN-C1-C6烷基,优选选自氢、甲基、乙基、异丙基、环丙基、2-羟基乙基、2-(N,N-二甲基氨基)乙基;R a、R b各自独立地选自氢、C1-C6烷基;优选地,R a、R b各自独立地选自H、甲基;X 1,X 2,X 3,X 4各自独立地选自C,CH,CH 2,N,NH,O,S;优选地,X 1,X 2,X 3,X 4各自独立地选自C、CH,N,O,S;更优选地,X 1,X 2,X 3,X 4各自独立地选自C,CH,N,S;Y 1,Y 2,Y 3,Y 4各自独立地选自C,CH,CH 2,N,NH,O,S;优选地,Y 1,Y 2,Y 3,Y 4各自独立地选自C,CH,N,O,S;更优选地,Y 1,Y 2,Y 3,Y 4各自独立地选自C,CH,N;R 3选自氢,卤素,卤代C1-C6烷基(例如,三氟甲基),氰基,硝基,C1-C6烷基(例如,甲基,乙基),C1-C6烷氧基(例如,甲氧基),C3-C6环烷基(例如,环丙基),C2-C6烯基(例如,乙烯基);优选地,R 3选自氢,卤素,卤代C1-C6烷基(例如,三氟甲基),C1-C6烷基(例如,甲基),C1-C6烷氧基(例如,甲氧基),C3-C6环烷基(例如,环丙基);更优选地,R 3选自氢,氟,氯,溴,三氟甲基,甲基,甲氧基,环丙基;R 4、R 5各自独立地选自氢、氟、氯、溴、碘、C1-C6烷基,且R 4、R 5不同时为氢;优选地,R 4、R 5各自独立地选自氢、氟、氯,且R 4、R 5不同时为氢;更优选地,R 4选自氟、氯,R 5为氢。
- 权利要求1的化合物,或所述化合物的立体异构体、其前药、其药学上可接受的盐或其药学上可接受的溶剂合物,其中,Z 6、Z 7各自独立地选自氢,C1-C6烷基,卤代C1-C6烷基,C3-C6环烷基,卤代C3-C6环烷基,或者,Z 6、Z 7与它们共同连接的N原子一起形成取代或未取代的含1~2个杂原子的4-8元杂环,所述取代基选自卤素,C1-C6烷基,C3-C8环烷基;优选地,Z 6、Z 7各自独立地选自氢,C1-C6烷基,C3-C6环烷基;或者优选地,Z 6、Z 7与它们共同连接的N原子一起形成含1-2个杂原子的4-8元杂环;更优选地,Z 6、Z 7各自独立地选自氢,C1-C6烷基,C3-C6环烷基,且Z 6、Z 7不同时为氢;或者更优选地,Z 6、Z 7与它们共同连接的N原子一起形成含1-2个(优选1个)杂原子(优选氮原子)的4-6元饱和杂环;进一步优选地,Z 6、Z 7各自独立地选自氢,甲基,乙基,异丙基,环丙基,且Z 6、Z 7不同时为氢;各L独立地选自直接键、C1-C6亚烷基;优选地,各L独立地选自直接键、亚甲基、亚乙基;各Y独立地选自氢、C1-C6烷基、C3-C6环烷基、HO-C1-C6烷基、R aR bN-C1-C6烷基;优选地,各Y独立地选自氢、甲基、乙基、异丙基、环丙基、2-羟基乙基、2-(N,N-二甲基氨基)乙基;各Z独立地选自氢、羟基、C1-C6烷基、C1-C6烷氧基、C3-C6环烷基、C3-C6环烷基-O-、HO-C1-C6烷基、R aR bN-、R aR bN-C1-C6烷基;优选地,各Z独立地选自氢、羟基、C1-C6烷基、C1-C6烷氧基、R aR bN-;更优选地,各Z独立地选自氢、羟基、C1-C6烷氧基、R aR bN-;最优选地,各Z独立地选自氢、羟基、氨基、N,N-二甲基氨基、甲氧基;优选地,R 1为 时,L选自直接键、C1-C6亚烷基,优选选自直接键、亚甲基、亚乙基;Y选自氢、C1-C6烷基、C3-C6环烷基、HO-C1-C6烷基、R aR bN-C1-C6烷基,优选选自氢、甲基、乙基、异丙基、环丙基、2-羟基乙基、2-(N,N-二甲基氨基)乙基;R a、R b各自独立地选自氢、C1-C6烷基;优选地,R a、R b各自独立地选自H、甲基;X 1,X 2,X 3,X 4各自独立地选自C,CH,CH 2,N,NH,O,S;优选地,X 1,X 2,X 3,X 4各自独立地选自C、CH,N,O,S;更优选地,X 1,X 2,X 3,X 4各自独立地选自C,CH,N,S;Y 1,Y 2,Y 3,Y 4各自独立地选自C,CH,CH 2,N,NH,O,S;优选地,Y 1,Y 2,Y 3,Y 4各自独立地选自C,CH,N,O,S;更优选地,Y 1,Y 2,Y 3,Y 4各自独立地选自C,CH,N;R 3选自氢,卤素,卤代C1-C6烷基(例如,三氟甲基),氰基,硝基,C1-C6烷基(例如,甲基,乙基),C1-C6烷氧基(例如,甲氧基),C3-C6环烷基(例如,环丙基),C2-C6烯基(例如,乙烯基);优选地,R 3选自氢,卤素,卤代C1-C6烷基(例如,三氟甲基),C1-C6烷基(例如,甲基),C1-C6烷氧基(例如,甲氧基),C3-C6环烷基(例如,环丙基);更优选地,R 3选自氢,氟,氯,溴,三氟甲基,甲基,甲氧基,环丙基;R 4、R 5各自独立地选自氢、氟、氯、溴、碘、C1-C6烷基,且R 4、R 5不同时为氢;优选地,R 4、R 5各自独立地选自氢、氟、氯,且R 4、R 5不同时为氢;更优选地,R 4选自氟、氯,R 5为氢。
- 制备权利要求中1-6任一项所述的化合物的方法,其包括以下步骤:反应条件:(a)酸性或碱性条件下的亲核取代反应;(b)金属钯催化的偶联反应,酸性条件下的亲核取代反应,或碱性条件下的亲核取代反应。其中:所述金属钯催化剂选自醋酸钯、四(三苯基膦)钯、双三苯基磷二氯化钯、[1,1'-双(二苯基膦)二茂铁]二氯化钯、三(二亚苄基丙酮)二钯;所述碱性条件指以下任意物质存在的条件:三乙胺、二异丙基乙基胺、吡啶、碳酸氢钠、碳酸钠、碳酸钾、碳酸铯、氢氧化锂、氢氧化钠、氢氧化钾、氢化钠、氢化钾;所述酸性条件指以下任意物质存在的条件:乙酸、三氟乙酸、盐酸、甲磺酸、对甲苯磺酸、樟脑磺酸;
- 药物组合物,其包含权利要求1-6中任一项的化合物或其立体异构体、其前药、其药学上可接受的盐或其药学上可接受的溶剂合物以及任选的药学上可以接受的赋形剂;优选地,所述药物组合物还包含其他肿瘤免疫治疗药物;更优选地,所述其他肿瘤免疫治疗药物选自PD-1单抗、PD-L1单抗、CTLA-4单抗、TIM-3单抗、TGFβ单抗、LAG3拮抗剂、TLR4激动剂、TLR7激动剂、TLR8激动剂、TLR9激动剂、STING激动剂、CAR-T细胞,或其任意组合。
- 权利要求1-6中任一项的化合物或其立体异构体、其前药、其药学上可接受的盐或其药学上可接受的溶剂合物或者权利要求8所述的药物组合物在制备药物中的用途,所述药物用于预防和/或治疗癌症或其他疾病,或者用于调节免疫应答,或者用于调节HPK1激酶活性和/或功能;优选地,所述癌症选自淋巴瘤、肉瘤、肺癌、非小细胞肺癌、小细胞肺癌、胃癌、肠癌、结肠癌、直肠癌、肺腺癌、胰腺癌、乳腺癌、***癌、肝癌、皮肤癌、上皮细胞癌、成胶质细胞瘤、胃肠间质瘤、白血病、鼻咽癌、胶质细胞瘤、子***、卵巢癌、膀胱癌、肾癌、甲状腺癌、外阴癌、***癌、***癌、食管癌、胆道肿瘤、头颈部癌、血液恶性肿瘤,或其任意组合。
- 预防和/治疗癌症或其他疾病的方法,其包括给予有需要的受试者预防和/或治疗有效量的权利要求1-6中任一项的化合物或其立体异构体、其前药、其药学上可接受的盐或其药学上可接受的溶剂合物或者权利要求8所述的药物组合物;优选地,所述癌症选自淋巴瘤、肉瘤、肺癌、非小细胞肺癌、小细胞肺癌、胃癌、肠癌、 结肠癌、直肠癌、肺腺癌、胰腺癌、乳腺癌、***癌、肝癌、皮肤癌、上皮细胞癌、成胶质细胞瘤、胃肠间质瘤、白血病、鼻咽癌、胶质细胞瘤、子***、卵巢癌、膀胱癌、肾癌、甲状腺癌、外阴癌、***癌、***癌、食管癌、胆道肿瘤、头颈部癌、血液恶性肿瘤,或其任意组合。
- 调节HPK1激酶活性和/或功能的方法,其包括给予有需要的受试者有效量的权利要求1-6中任一项的化合物或其立体异构体、其前药、其药学上可接受的盐或其药学上可接受的溶剂合物或者权利要求8所述的药物组合物。
- 调节免疫应答的方法,其包括给予有需要的受试者有效量的权利要求1-6中任一项的化合物或其立体异构体、其前药、其药学上可接受的盐或其药学上可接受的溶剂合物或者权利要求8所述的药物组合物。
- 权利要求1-6中任一项的化合物或其立体异构体、其前药、其药学上可接受的盐或其药学上可接受的溶剂合物或者权利要求8所述的药物组合物,其用于预防和/或治疗癌症或其他疾病,或者用于调节免疫应答,或者用于调节HPK1激酶活性和/或功能;优选地,所述癌症选自淋巴瘤、肉瘤、肺癌、非小细胞肺癌、小细胞肺癌、胃癌、肠癌、结肠癌、直肠癌、肺腺癌、胰腺癌、乳腺癌、***癌、肝癌、皮肤癌、上皮细胞癌、成胶质细胞瘤、胃肠间质瘤、白血病、鼻咽癌、胶质细胞瘤、子***、卵巢癌、膀胱癌、肾癌、甲状腺癌、外阴癌、***癌、***癌、食管癌、胆道肿瘤、头颈部癌、血液恶性肿瘤,或其任意组合。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202180075195.4A CN116438172A (zh) | 2020-11-13 | 2021-11-12 | Hpk1激酶调节剂、其制备方法与应用 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202011268336.8 | 2020-11-13 | ||
CN202011268336 | 2020-11-13 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022100688A1 true WO2022100688A1 (zh) | 2022-05-19 |
Family
ID=81602140
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/130283 WO2022100688A1 (zh) | 2020-11-13 | 2021-11-12 | Hpk1激酶调节剂、其制备方法与应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN116438172A (zh) |
WO (1) | WO2022100688A1 (zh) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11897878B2 (en) | 2018-10-31 | 2024-02-13 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
US11925631B2 (en) | 2018-10-31 | 2024-03-12 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018102366A1 (en) * | 2016-11-30 | 2018-06-07 | Ariad Pharmaceuticals, Inc. | Anilinopyrimidines as haematopoietic progenitor kinase 1 (hpk1) inhibitors |
WO2019015655A1 (zh) * | 2017-07-19 | 2019-01-24 | 正大天晴药业集团股份有限公司 | 作为egfr激酶抑制剂的芳基磷氧化合物 |
WO2020188467A1 (zh) * | 2019-03-15 | 2020-09-24 | 杭州英创医药科技有限公司 | 作为激酶抑制剂的稠合三环化合物 |
WO2020200191A1 (en) * | 2019-04-04 | 2020-10-08 | Betta Pharmaceuticals Co., Ltd | Egfr inhibitors, compositions and methods there of |
WO2020216371A1 (zh) * | 2019-04-26 | 2020-10-29 | 江苏先声药业有限公司 | Egfr抑制剂及其应用 |
WO2020253862A1 (zh) * | 2019-06-21 | 2020-12-24 | 上海翰森生物医药科技有限公司 | 含氮芳基磷氧化物类衍生物、其制备方法和应用 |
WO2021104305A1 (zh) * | 2019-11-26 | 2021-06-03 | 上海翰森生物医药科技有限公司 | 含氮多环类衍生物抑制剂、其制备方法和应用 |
CN113717156A (zh) * | 2020-05-25 | 2021-11-30 | 南京红云生物科技有限公司 | Egfr抑制剂、其制备方法及用途 |
WO2021249324A1 (zh) * | 2020-06-08 | 2021-12-16 | 南京红云生物科技有限公司 | 烯基嘧啶类化合物、其制备方法与应用 |
-
2021
- 2021-11-12 CN CN202180075195.4A patent/CN116438172A/zh active Pending
- 2021-11-12 WO PCT/CN2021/130283 patent/WO2022100688A1/zh active Application Filing
Patent Citations (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018102366A1 (en) * | 2016-11-30 | 2018-06-07 | Ariad Pharmaceuticals, Inc. | Anilinopyrimidines as haematopoietic progenitor kinase 1 (hpk1) inhibitors |
WO2019015655A1 (zh) * | 2017-07-19 | 2019-01-24 | 正大天晴药业集团股份有限公司 | 作为egfr激酶抑制剂的芳基磷氧化合物 |
WO2020188467A1 (zh) * | 2019-03-15 | 2020-09-24 | 杭州英创医药科技有限公司 | 作为激酶抑制剂的稠合三环化合物 |
WO2020200191A1 (en) * | 2019-04-04 | 2020-10-08 | Betta Pharmaceuticals Co., Ltd | Egfr inhibitors, compositions and methods there of |
WO2020216371A1 (zh) * | 2019-04-26 | 2020-10-29 | 江苏先声药业有限公司 | Egfr抑制剂及其应用 |
WO2020253862A1 (zh) * | 2019-06-21 | 2020-12-24 | 上海翰森生物医药科技有限公司 | 含氮芳基磷氧化物类衍生物、其制备方法和应用 |
WO2021104305A1 (zh) * | 2019-11-26 | 2021-06-03 | 上海翰森生物医药科技有限公司 | 含氮多环类衍生物抑制剂、其制备方法和应用 |
CN113717156A (zh) * | 2020-05-25 | 2021-11-30 | 南京红云生物科技有限公司 | Egfr抑制剂、其制备方法及用途 |
WO2021249324A1 (zh) * | 2020-06-08 | 2021-12-16 | 南京红云生物科技有限公司 | 烯基嘧啶类化合物、其制备方法与应用 |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11897878B2 (en) | 2018-10-31 | 2024-02-13 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
US11925631B2 (en) | 2018-10-31 | 2024-03-12 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds |
Also Published As
Publication number | Publication date |
---|---|
CN116438172A (zh) | 2023-07-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11306106B2 (en) | Pharmaceutical compositions containing substituted polycyclic pyridone derivatives and prodrug thereof | |
US7517873B2 (en) | Substituted pyrimidodiazepines | |
WO2022100688A1 (zh) | Hpk1激酶调节剂、其制备方法与应用 | |
US9493440B2 (en) | Compounds inhibiting leucine-rich repeat kinase enzyme activity | |
US8604023B2 (en) | 1,4-benzodiazepinone compounds and their use in treating cancer | |
US20180244611A1 (en) | Modulators of the Cystic Fibrosis Transmembrane Conductance Regulator Protein and Methods of Use | |
US11827625B2 (en) | Pyrimidine derivative, method for preparing same and use thereof in medicine | |
EP3409667A1 (en) | Amide compounds for the treatment of hiv infections | |
WO2021143822A1 (zh) | 并环酰亚胺类衍生物、其制备方法及其在医药上的应用 | |
RU2748696C2 (ru) | Пиридиновые соединения, содержащие семь атомов в кольце, способ их получения, фармацевтическая композиция, содержащая указанные соединения, и их применение | |
TW200840581A (en) | Novel pyrimidine derivatives | |
IE57739B1 (en) | 9a-aza-9a-homoerythromycin derivatives | |
WO2021238827A1 (zh) | Egfr抑制剂、其制备方法及用途 | |
WO2021143816A1 (zh) | 稠合酰亚胺类衍生物、其制备方法及其在医药上的应用 | |
US20230405008A1 (en) | Treatment of hematological malignancies with inhibitors of menin | |
KR20220006104A (ko) | 유비퀴틴화 특이적 프로테아제 억제제 및 이의 제조 방법과 응용 | |
CN112654622A (zh) | 并环化合物、其制备方法及用途 | |
US20230100158A1 (en) | Fibroblast activation protein (fap) - targeted antifibrotic therapy | |
CA3012179A1 (en) | Triazole derivatives of melampomagnolide b and methods of use thereof | |
TW202214590A (zh) | 烯基嘧啶類化合物、其製備方法與應用 | |
CN112898312B (zh) | 一种稠合多环吡啶酮衍生物及其用途 | |
WO2022184103A1 (zh) | 三并环化合物及其药物组合物和应用 | |
CN117304182A (zh) | 一类具有嘧啶并六元环结构的化合物、包含其的药物组合物及其应用 | |
US20050069999A1 (en) | Sh3 domain binding inhibitors | |
WO2023179567A1 (zh) | 作为Toll样受体激动剂的嘧啶并哒嗪酮类化合物 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21891208 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21891208 Country of ref document: EP Kind code of ref document: A1 |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21891208 Country of ref document: EP Kind code of ref document: A1 |
|
32PN | Ep: public notification in the ep bulletin as address of the adressee cannot be established |
Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 10/11/2023) |